<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATRIPLA - efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet, film coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ATRIPLA safely and effectively. See full prescribing information for ATRIPLA. <br> <br>ATRIPLA<span class="Sup">®</span> (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets<br><br>Initial U.S. Approval: 2006</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of ATRIPLA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">ATRIPLA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients coinfected with HBV and HIV-1 who have discontinued EMTRIVA or VIREAD, two of the components of ATRIPLA. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="60%">
<col align="left" valign="middle" width="70%">
<col align="right" valign="middle" width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Boxed Warning</td>
<td align="right">1/2010</td>
</tr>
<tr>
<td align="left">Warnings and Precautions</td>
<td align="right"></td>
</tr>
<tr>
<td align="left">  Patients Coinfected with HIV-1 and HBV (<a href="#S5.2">5.2</a>)</td>
<td align="right">1/2010</td>
</tr>
<tr>
<td align="left">  New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#S5.7">5.7</a>)</td>
<td align="right">1/2010</td>
</tr>
<tr>
<td align="left">  Reproductive Risk Potential (<a href="#S5.8">5.8</a>)</td>
<td align="right">1/2010</td>
</tr>
<tr class="Botrule Last">
<td align="left">  Decrease in Bone Mineral Density (<a href="#S5.11">5.11</a>)</td>
<td align="right">1/2010</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of ATRIPLA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">ATRIPLA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients coinfected with HBV and HIV-1 who have discontinued EMTRIVA or VIREAD, two of the components of ATRIPLA. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ATRIPLA, a combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor, is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults.  (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended dose: One tablet once daily taken orally on an empty stomach, preferably at bedtime.  (<a href="#S2">2</a>)</li>
<li>Dose in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Should not be administered in patients with creatinine clearance &lt;50 mL/min. (<a href="#S2">2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablet containing 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate.  (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) to efavirenz, a component of ATRIPLA. (<a href="#S4.1">4.1</a>)</li>
<li>For some drugs, competition for CYP3A by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, prolonged sedation, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>). (<a href="#S4.2">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>: Immediate medical evaluation is recommended.  (<a href="#S5.5">5.5</a>, <a href="#S6.1">6.1</a>)</li>
<li>Nervous system symptoms (NSS): NSS are frequent, usually begin 1–2 days after initiating therapy and resolve in 2–4 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset of <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>.  (<a href="#S2">2</a>, <a href="#S5.6">5.6</a>)</li>
<li>New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Can include <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>. Assess creatinine clearance (CrCl) before initiating treatment with ATRIPLA. Monitor CrCl and serum phosphorus in patients at risk. Avoid administering ATRIPLA with concurrent or recent use of nephrotoxic drugs.  (<a href="#S5.7">5.7</a>)</li>
<li>Pregnancy: Fetal harm can occur when administered to a pregnant woman during the first trimester. Women should be apprised of the potential harm to the fetus. (<a href="#S5.8">5.8</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>: Discontinue if severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops.  (<a href="#S5.9">5.9</a>, <a href="#S6.1">6.1</a>)</li>
<li>Hepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and C, or marked transaminase elevations. (<a href="#S5.10">5.10</a>, <a href="#S8.6">8.6</a>)</li>
<li>Decreases in bone mineral density (BMD): Consider monitoring BMD in patients with a history of <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span> or who are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>.  (<a href="#S5.11">5.11</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>: Use caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (<a href="#S5.12">5.12</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span>: May necessitate further evaluation and treatment.  (<a href="#S5.13">5.13</a>)</li>
<li>Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy.  (<a href="#S5.14">5.14</a>)</li>
<li>Coadministration with other products: Do not use with drugs containing efavirenz, emtricitabine or tenofovir disoproxil fumarate including SUSTIVA, TRUVADA, EMTRIVA, VIREAD; or with drugs containing lamivudine. Do not administer in combination with HEPSERA.  (<a href="#S5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥10%) observed in an active-controlled clinical study of efavirenz, emtricitabine, and tenofovir DF are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  (<a href="#S6">6</a>) </p>
<p class="Highlighta"> <br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Efavirenz:  Coadministration of efavirenz can alter the concentrations of other drugs and other drugs may alter the concentrations of efavirenz. The potential for drug-drug interactions must be considered before and during therapy. (<a href="#S4.2">4.2</a>, <a href="#S7.1">7.1</a>, <a href="#S12.3">12.3</a>)</li>
<li>Didanosine: Tenofovir disoproxil fumarate increases didanosine concentrations. Use with caution and monitor for evidence of didanosine toxicity (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>) when coadministered. Consider dose reductions or discontinuations of didanosine if warranted. (<a href="#S7.2">7.2</a>)</li>
<li>Atazanavir: Coadministration of ATRIPLA and atazanavir or atazanavir/ritonavir is not recommended.   (<a href="#S7.3">7.3</a>)</li>
<li>Lopinavir/ritonavir: Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity.  (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy:   Women should avoid pregnancy while receiving ATRIPLA and for 12 weeks after discontinuation. (<a href="#S5.8">5.8</a>)</li>
<li>Nursing mothers: Women infected with HIV should be instructed not to breast feed.  (<a href="#S8.3">8.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C coinfection or therapy with medications associated with liver toxicity: Use caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#S5.10">5.10</a>, <a href="#S6.2">6.2</a>, <a href="#S8.6">8.6</a>)</li>
<li>Pediatrics:  Safety and efficacy not established in patients less than 18 years of age.  (<a href="#S2">2</a>, <a href="#S8.4">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"></a></h2>
<h2><a href="#section-2.2" class="toc"></a></h2>
<h2><a href="#section-2.3" class="toc"></a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2	Contraindicated Drugs</a></h2>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Patients Coinfected with HIV-1 and HBV</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Drug Interactions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Coadministration with Related Products</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Nervous System Symptoms</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.9" class="toc"></a></h2>
<h2><a href="#section-5.10" class="toc"></a></h2>
<h2><a href="#section-5.11" class="toc"></a></h2>
<h2><a href="#section-5.12" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.10	Liver Enzymes</a></h2>
<h2><a href="#section-5.14" class="toc">5.11	Decreases in Bone Mineral Density</a></h2>
<h2><a href="#section-5.15" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.13	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> </a></h2>
<h2><a href="#section-5.17" class="toc">5.14	Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"></a></h2>
<h2><a href="#section-6.2" class="toc">6.1	Adverse Reactions from Clinical Trials Experience</a></h2>
<h2><a href="#section-6.3" class="toc"></a></h2>
<h2><a href="#section-6.4" class="toc"></a></h2>
<h2><a href="#section-6.5" class="toc"></a></h2>
<h2><a href="#section-6.6" class="toc"></a></h2>
<h2><a href="#section-6.7" class="toc"></a></h2>
<h2><a href="#section-6.9" class="toc"></a></h2>
<h2><a href="#section-6.10" class="toc"></a></h2>
<h2><a href="#section-6.11" class="toc">6.3	Postmarketing Experience</a></h2>
<h2><a href="#section-6.12" class="toc"></a></h2>
<h2><a href="#section-6.13" class="toc"></a></h2>
<h2><a href="#section-6.14" class="toc"></a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Efavirenz</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Emtricitabine and Tenofovir Disoproxil Fumarate  </a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate   </a></h2>
<h2><a href="#section-7.5" class="toc"></a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc"></a></h2>
<h2><a href="#section-9.2" class="toc"></a></h2>
<h2><a href="#section-9.3" class="toc"></a></h2>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc"></a></h2>
<h2><a href="#section-10.2" class="toc"></a></h2>
<h2><a href="#section-10.3" class="toc"></a></h2>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.3" class="toc"></a></h2>
<h2><a href="#section-11.4" class="toc"></a></h2>
<h2><a href="#section-11.5" class="toc"></a></h2>
<h2><a href="#section-11.6" class="toc"></a></h2>
<h2><a href="#section-11.7" class="toc"></a></h2>
<h2><a href="#section-11.8" class="toc"></a></h2>
<h2><a href="#section-11.9" class="toc"></a></h2>
<h2><a href="#section-11.10" class="toc"></a></h2>
<h2><a href="#section-11.11" class="toc"></a></h2>
<h2><a href="#section-11.12" class="toc"></a></h2>
<h2><a href="#section-11.13" class="toc"></a></h2>
<h2><a href="#section-11.14" class="toc"></a></h2>
<h2><a href="#section-11.15" class="toc"></a></h2>
<h2><a href="#section-11.16" class="toc"></a></h2>
<h2><a href="#section-11.17" class="toc"></a></h2>
<h2><a href="#section-11.18" class="toc"></a></h2>
<h2><a href="#section-11.19" class="toc"></a></h2>
<h2><a href="#section-11.20" class="toc"></a></h2>
<h2><a href="#section-11.21" class="toc"></a></h2>
<h2><a href="#section-11.22" class="toc"></a></h2>
<h2><a href="#section-11.23" class="toc"></a></h2>
<h2><a href="#section-11.24" class="toc"></a></h2>
<h2><a href="#section-11.25" class="toc"></a></h2>
<h2><a href="#section-11.27" class="toc"></a></h2>
<h2><a href="#section-11.28" class="toc"></a></h2>
<h2><a href="#section-11.29" class="toc"></a></h2>
<h2><a href="#section-11.30" class="toc"></a></h2>
<h2><a href="#section-11.31" class="toc"></a></h2>
<h2><a href="#section-11.32" class="toc"></a></h2>
<h2><a href="#section-11.33" class="toc"></a></h2>
<h2><a href="#section-11.34" class="toc"></a></h2>
<h2><a href="#section-11.35" class="toc"></a></h2>
<h2><a href="#section-11.36" class="toc"></a></h2>
<h2><a href="#section-11.37" class="toc"></a></h2>
<h2><a href="#section-11.38" class="toc"></a></h2>
<h2><a href="#section-11.39" class="toc"></a></h2>
<h2><a href="#section-11.40" class="toc"></a></h2>
<h2><a href="#section-11.41" class="toc"></a></h2>
<h2><a href="#section-11.42" class="toc"></a></h2>
<h2><a href="#section-11.43" class="toc"></a></h2>
<h2><a href="#section-11.44" class="toc"></a></h2>
<h2><a href="#section-11.45" class="toc"></a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.2" class="toc"></a></h2>
<h2><a href="#section-12.3" class="toc"></a></h2>
<h2><a href="#section-12.4" class="toc"></a></h2>
<h2><a href="#section-12.6" class="toc"></a></h2>
<h2><a href="#section-12.7" class="toc"></a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"></a></h2>
<h2><a href="#section-13.2" class="toc"></a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION and FDA-APPROVED PATIENT LABELING</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Drug Interactions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Information for Patients</a></h2>
<h2><a href="#section-15.3" class="toc">17.3	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-15.4" class="toc">17.4	Patients Coinfected with HIV-1 and HBV</a></h2>
<h2><a href="#section-15.5" class="toc">17.5	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6	Decreases in Bone Mineral Density</a></h2>
<h2><a href="#section-15.7" class="toc">17.7	Dosing Instructions</a></h2>
<h2><a href="#section-15.8" class="toc">17.8	Nervous System Symptoms</a></h2>
<h2><a href="#section-15.9" class="toc">17.9	<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></a></h2>
<h2><a href="#section-15.10" class="toc">17.10	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-15.11" class="toc">17.11	Reproductive Risk Potential</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Box"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of ATRIPLA, in combination with other antiretrovirals <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></span></p>
<p><span class="Bold">ATRIPLA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the safety and efficacy of ATRIPLA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued EMTRIVA or VIREAD, which are components of ATRIPLA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue ATRIPLA. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">ATRIPLA<span class="Sup">® </span>is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Adults:</span>  The dose of ATRIPLA is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may improve the tolerability of nervous system symptoms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pediatrics:</span>  ATRIPLA is not recommended for use in patients &lt;18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>  Because ATRIPLA is a fixed-dose combination, it should not be prescribed for patients requiring dosage adjustment such as those with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;50 mL/min).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ATRIPLA is available as tablets. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (tenofovir DF, which is equivalent to 245 mg of tenofovir disoproxil). The tablets are pink, capsule-shaped, film-coated, debossed with "123" on one side and plain-faced on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">ATRIPLA is contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) to efavirenz, a component of ATRIPLA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	Contraindicated Drugs</h2>
<p class="First">For some drugs, competition for CYP3A by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, prolonged sedation, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>). Drugs that are contraindicated with ATRIPLA are listed in Table 1.</p>
<table width="100%">
<caption><span>Table 1 Drugs That Are Contraindicated or Not Recommended for Use With ATRIPLA</span></caption>
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Drug Class: Drug  Name</th>
<th class="Rrule" align="center">Clinical Comment</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Antifungal: voriconazole</td>
<td class="Rrule" align="left">Efavirenz significantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole. Also, voriconazole significantly increases efavirenz plasma concentrations, which may increase the risk of efavirenz-associated side effects. Because ATRIPLA is a fixed-dose combination product, the dose of efavirenz cannot be altered. <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a><a href="#table5"> Tables 5</a> and <a href="#table6">6</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine)</td>
<td class="Rrule" align="left">Potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Benzodiazepines: midazolam, triazolam</td>
<td class="Rrule" align="left">Potential for serious and/or life-threatening reactions such as prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Calcium channel blocker: bepridil</td>
<td class="Rrule" align="left">Potential for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">GI motility agent: cisapride</td>
<td class="Rrule" align="left">Potential for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Neuroleptic: pimozide</td>
<td class="Rrule" align="left">Potential for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">St. John's wort (<span class="Italics">Hypericum perforatum</span>)</td>
<td class="Rrule" align="left">May lead to loss of virologic response and possible resistance to efavirenz or to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs).</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs including tenofovir DF, a component of ATRIPLA, in combination with other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with ATRIPLA should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Patients Coinfected with HIV-1 and HBV</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">It is recommended that all patients with HIV-1 be tested for the presence of chronic HBV before initiating antiretroviral therapy. ATRIPLA is not approved for the treatment of chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and the safety and efficacy of ATRIPLA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir DF, two of the components of ATRIPLA. In some patients infected with HBV and treated with emtricitabine, the exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B were associated with liver decompensation and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Patients who are coinfected with HIV-1 and HBV should be closely monitored with both clinical and laboratory follow up for at least several months after stopping treatment with ATRIPLA. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">ATRIPLA should not be administered with HEPSERA<span class="Sup">®</span> (adefovir dipivoxil) <span class="Italics">[See <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Drug Interactions</h2>
<p class="First">Efavirenz plasma concentrations may be altered by substrates, inhibitors, or inducers of CYP3A. Likewise, efavirenz may alter plasma concentrations of drugs metabolized by CYP3A <span class="Italics">[See <a href="#S4.2">Contraindications (4.2)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Coadministration with Related Products</h2>
<p class="First">Related drugs not for coadministration with ATRIPLA include EMTRIVA (emtricitabine), VIREAD (tenofovir DF), TRUVADA (emtricitabine/tenofovir DF), and SUSTIVA (efavirenz), which contain the same active components as ATRIPLA. Due to similarities between emtricitabine and lamivudine, ATRIPLA should not be coadministered with drugs containing lamivudine, including Combivir (lamivudine/zidovudine), Epivir, or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), or Trizivir (abacavir sulfate/lamivudine/zidovudine). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></h2>
<p class="First">Serious psychiatric adverse experiences have been reported in patients treated with efavirenz. In controlled trials of 1008 subjects treated with regimens containing efavirenz for a mean of 2.1 years and 635 subjects treated with control regimens for a mean of 1.5 years, the frequency (regardless of causality) of specific serious psychiatric events among subjects who received efavirenz or control regimens, respectively, were: severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (2.4%, 0.9%), <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (0.7%, 0.3%), nonfatal <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> (0.5%, 0%), <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> (0.4%, 0.5%), <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reactions</span> (0.4%, 0.3%), and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span> (0.2%, 0.3%). When <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> similar to those noted above were combined and evaluated as a group in a multifactorial analysis of data from Study AI266006 (006), treatment with efavirenz was associated with an increase in the occurrence of these selected <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>. Other factors associated with an increase in the occurrence of these <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> were history of injection drug use, psychiatric history, and receipt of psychiatric medication at study entry; similar associations were observed in both the efavirenz and control treatment groups. In Study 006, onset of new serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> occurred throughout the study for both efavirenz-treated and control-treated subjects. One percent of efavirenz-treated subjects discontinued or interrupted treatment because of one or more of these selected <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>. There have also been occasional postmarketing reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> by <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>-like behavior, although a causal relationship to the use of efavirenz cannot be determined from these reports. Patients with serious psychiatric adverse experiences should seek immediate medical evaluation to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risks of continued therapy outweigh the benefits <span class="Italics">[See <a href="#S6">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Nervous System Symptoms</h2>
<p class="First">Fifty-three percent (531/1008) of subjects receiving efavirenz in controlled trials reported central nervous system symptoms (any grade, regardless of causality) compared to 25% (156/635) of subjects receiving control regimens. These symptoms included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (28.1% of the 1008 subjects), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (16.3%), impaired concentration (8.3%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (7.0%), <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span> (6.2%), and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (1.2%). Other reported symptoms were <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>. The majority of these symptoms were mild-moderate (50.7%); symptoms were severe in 2.0% of subjects. Overall, 2.1% of subjects discontinued therapy as a result. These symptoms usually begin during the first or second day of therapy and generally resolve after the first 2–4 weeks of therapy. After 4 weeks of therapy, the prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in subjects treated with regimens containing efavirenz and from 3% to 5% in subjects treated with a control regimen. Patients should be informed that these common symptoms were likely to improve with continued therapy and were not predictive of subsequent onset of the less frequent <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>. Dosing at bedtime may improve the tolerability of these nervous system symptoms <span class="Italics">[See <a href="#S2">Dosage and Administration (2)</a>]</span>.</p>
<p>Analysis of long-term data from Study 006, (median follow-up 180 weeks, 102 weeks, and 76 weeks for subjects treated with efavirenz + zidovudine + lamivudine, efavirenz + indinavir, and indinavir + zidovudine + lamivudine, respectively) showed that, beyond 24 weeks of therapy, the incidences of new-onset nervous system symptoms among efavirenz-treated subjects were generally similar to those in the indinavir-containing control arm.</p>
<p>Patients receiving ATRIPLA should be alerted to the potential for additive central nervous system effects when ATRIPLA is used concomitantly with alcohol or psychoactive drugs.</p>
<p>Patients who experience central nervous system symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, impaired concentration, and/or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> should avoid potentially hazardous tasks such as driving or operating machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Emtricitabine and tenofovir are principally eliminated by the kidney; however, efavirenz is not. Since ATRIPLA is a combination product and the dose of the individual components cannot be altered, patients with creatinine clearance &lt;50 mL/min should not receive ATRIPLA.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span> (renal tubular injury with severe <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>), has been reported with the use of tenofovir DF <span class="Italics">[See <a href="#S6.3">Adverse Reactions (6.3)</a>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with ATRIPLA. Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients at risk for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including patients who have previously experienced renal events while receiving HEPSERA.</span></p>
<p>ATRIPLA should be avoided with concurrent or recent use of a nephrotoxic agent. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Reproductive Risk Potential</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pregnancy Category D: </span> Efavirenz may cause fetal harm when administered during the first trimester to a pregnant woman. Pregnancy should be avoided in women receiving ATRIPLA. Barrier contraception must always be used in combination with other methods of contraception (e.g., oral or other hormonal contraceptives). Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of ATRIPLA is recommended. Women of childbearing potential should undergo pregnancy testing before initiation of ATRIPLA. If this drug is used during the first trimester of pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.</p>
<p>There are no adequate and well-controlled studies of ATRIPLA in pregnant women. ATRIPLA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, such as in pregnant women without other therapeutic options.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiretroviral Pregnancy Registry: </span> To monitor fetal outcomes of pregnant women, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients who become pregnant by calling (800) 258-4263.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-5.11"></a><p></p>
<h2></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Efavirenz: </span> As of July 2008, the Antiretroviral Pregnancy Registry has received prospective reports of 526 pregnancies exposed to efavirenz-containing regimens, nearly all of which were first-trimester exposures (507 pregnancies). <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> occurred in 13 of 407 live births (first-trimester exposure) and 2 of 37 live births (second/third-trimester exposure). One of these prospectively reported defects with first-trimester exposure was a <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span>. A single case of <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span> with first-trimester exposure to efavirenz has also been prospectively reported; however, this case included severe oblique facial clefts and amniotic banding, a known association with <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>. There have been five retrospective reports of findings consistent with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, including <span class="product-label-link" type="condition" conceptid="4212197" conceptname="Meningomyelocele">meningomyelocele</span>. All mothers were exposed to efavirenz-containing regimens in the first trimester. Although a causal relationship of these events to the use of efavirenz has not been established, similar defects have been observed in preclinical studies of efavirenz.</span></p>
<p>Malformations have been observed in 3 of 20 fetuses/infants from efavirenz-treated cynomolgus monkeys (versus 0 of 20 concomitant controls) in a developmental toxicity study. The pregnant monkeys were dosed throughout pregnancy (postcoital days 20–150) with efavirenz 60 mg/kg daily, a dose which resulted in plasma drug concentrations similar to those in humans given 600 mg/day of efavirenz. <span class="product-label-link" type="condition" conceptid="377368" conceptname="Anencephalus">Anencephaly</span> and unilateral <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span> were observed in one fetus, microophthalmia was observed in another fetus, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> was observed in a third fetus. Efavirenz crosses the placenta in cynomolgus monkeys and produces fetal blood concentrations similar to maternal blood concentrations. Efavirenz has been shown to cross the placenta in rats and rabbits and produces fetal blood concentrations of efavirenz similar to maternal concentrations. An increase in fetal resorptions was observed in rats at efavirenz doses that produced peak plasma concentrations and AUC values in female rats equivalent to or lower than those achieved in humans given 600 mg once daily of efavirenz. Efavirenz produced no reproductive toxicities when given to pregnant rabbits at doses that produced peak plasma concentrations similar to and AUC values approximately half of those achieved in humans given 600 mg once daily of efavirenz.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.12"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">In controlled clinical trials, 26% (266/1008) of subjects treated with 600 mg efavirenz experienced new-onset <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> compared with 17% (111/635) of subjects treated in control groups. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> associated with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, moist <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, or ulceration occurred in 0.9% (9/1008) of subjects treated with efavirenz. The incidence of Grade 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (e.g., <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) in subjects treated with efavirenz in all studies and expanded access was 0.1%. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> are usually mild-to-moderate maculopapular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> that occur within the first 2 weeks of initiating therapy with efavirenz (median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in adults was 11 days) and, in most subjects continuing therapy with efavirenz, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> resolves within 1 month (median duration, 16 days). The discontinuation rate for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in clinical trials was 1.7% (17/1008). ATRIPLA can be reinitiated in patients interrupting therapy because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. ATRIPLA should be discontinued in patients developing severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, mucosal involvement, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Experience with efavirenz in subjects who discontinued other antiretroviral agents of the NNRTI class is limited. Nineteen subjects who discontinued nevirapine because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have been treated with efavirenz. Nine of these subjects developed mild-to-moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> while receiving therapy with efavirenz, and two of these subjects discontinued because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.13"></a><p></p>
<h2>5.10	Liver Enzymes</h2>
<p class="First">In patients with known or suspected history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and in patients treated with other medications associated with liver toxicity, monitoring of liver enzymes is recommended <span class="Italics">[See also <a href="#S5.2">Warnings and Precautions (5.2)</a>]. </span>In patients with persistent elevations of serum transaminases to greater than five times the upper limit of the normal range, the benefit of continued therapy with ATRIPLA needs to be weighed against the unknown risks of significant liver toxicity <span class="Italics">[See <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.14"></a><p></p>
<h2>5.11	Decreases in Bone Mineral Density</h2>
<p class="First">Bone mineral density (BMD) monitoring should be considered for HIV-1 infected subjects who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients. If bone abnormalities are suspected then appropriate consultation should be obtained.</p>
<p>In a 144-week study of treatment-naive subjects receiving tenofovir DF, decreases in BMD were seen at the lumbar spine and hip in both arms of the study. At Week 144, there was a significantly greater mean percentage decrease from baseline in BMD at the lumbar spine in subjects receiving tenofovir DF + lamivudine + efavirenz compared with subjects receiving stavudine + lamivudine + efavirenz. Changes in BMD at the hip were similar between the two treatment groups. In both groups, the majority of the reduction in BMD occurred in the first 24–48 weeks of the study and this reduction was sustained through 144 weeks. Twenty-eight percent of tenofovir DF-treated subjects vs. 21% of the comparator subjects lost at least 5% of BMD at the spine or 7% of BMD at the hip. Clinically relevant <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (excluding fingers and toes) were reported in 4 subjects in the tenofovir DF group and 6 subjects in the comparator group. Tenofovir DF was associated with significant increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide), suggesting increased bone turnover. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving tenofovir DF. The effects of tenofovir DF-associated changes in BMD and biochemical markers on long-term bone health and future <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk are unknown. For additional information, consult the tenofovir DF prescribing information.</p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (associated with proximal renal tubulopathy and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) have been reported in association with the use of tenofovir DF <span class="Italics">[See <a href="#S6.3">Adverse Reactions (6.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.15"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been observed in patients receiving efavirenz, generally in the presence of known medical history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Caution must be taken in any patient with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Patients who are receiving concomitant anticonvulsant medications primarily metabolized by the liver, such as phenytoin and phenobarbital, may require periodic monitoring of plasma levels <span class="Italics">[See <a href="#S7.3">Drug Interactions (7.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.16"></a><p></p>
<h2>5.13	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including the components of ATRIPLA. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>], which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.17"></a><p></p>
<h2>5.14	Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  The following adverse reactions are discussed in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span>
</li>
<li>Severe Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span> <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>].</span>
</li>
<li>Nervous System Symptoms <span class="Italics">[See <a href="#S5.6">Warnings and Precautions (5.6)</a>].</span>
</li>
<li>New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <span class="Italics">[See <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <span class="Italics">[See <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span>
</li>
<li>Decreases in Bone Mineral Density <span class="Italics">[See <a href="#S5.11">Warnings and Precautions (5.11)</a>].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> <span class="Italics">[See <a href="#S5.13">Warnings and Precautions (5.13)</a>].</span>
</li>
<li>Drug Interactions <span class="Italics">[See <a href="#S4.2">Contraindications (4.2)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a> and <a href="#S7">Drug Interactions (7)</a>].</span>
</li>
</ul>
<p>For additional safety information about SUSTIVA (efavirenz), EMTRIVA (emtricitabine), or VIREAD (tenofovir DF) in combination with other antiretroviral agents, consult the prescribing information for these products. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.2"></a><p></p>
<h2>6.1	Adverse Reactions from Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 934</span></p>
<p>Study 934 was an open-label active-controlled study in which 511 antiretroviral-naive subjects received either emtricitabine + tenofovir DF administered in combination with efavirenz (N=257) or zidovudine/lamivudine administered in combination with efavirenz (N=254). </p>
<p>The most common adverse reactions (incidence ≥ 10%, any severity) occurring in Study 934 include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Adverse reactions observed in Study 934 were generally consistent with those seen in previous studies of the individual components (Table 2).</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2 Selected Treatment-Emergent Adverse Reactions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (Grades 2–4) Reported in ≥5% in Either Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">FTC + TDF + EFV<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>From Weeks 96 to 144 of the study, subjects received emtricitabine/tenofovir DF administered in combination with efavirenz in place of emtricitabine + tenofovir DF with efavirenz.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">General Disorders and Administration Site Condition</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule" align="left">Psychiatric Disorders</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule" align="left">Skin and Subcutaneous Tissue Disorders</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Event<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 073</span></p>
<p>In Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no history of virologic failure were randomized to receive ATRIPLA or to stay on their baseline regimen. The adverse reactions observed in Study 073 were generally consistent with those seen in Study 934 and those seen with the individual components of ATRIPLA when each was administered in combination with other antiretroviral agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine, or Tenofovir Disoproxil Fumarate</span></p>
<p>In addition to the adverse reactions in Study 934 and Study 073 the following adverse reactions were observed in clinical trials of efavirenz, emtricitabine, or tenofovir DF in combination with other antiretroviral agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz: </span>The most significant adverse reactions observed in subjects treated with efavirenz are nervous system symptoms <span class="Italics">[See <a href="#S5.6">Warnings and Precautions (5.6)</a>],</span> <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>],</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[See <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Selected adverse reactions of moderate-severe intensity observed in ≥2% of efavirenz-treated subjects in two controlled clinical trials included <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, impaired concentration, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has also been reported, although a causal relationship with efavirenz has not been established. Asymptomatic increases in serum amylase levels were observed in a significantly higher number of subjects treated with efavirenz 600 mg than in control subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  Adverse reactions that occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in clinical trials include <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> event (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span> has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic. The mechanism and clinical significance are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.8"></a><p></p>
<h2>6.2 	Laboratory Abnormalities</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate: </span> Laboratory abnormalities observed in Study 934 were generally consistent with those seen in previous studies (Table 3).</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 Significant Laboratory Abnormalities Reported in ≥1% of Subjects in Either Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">FTC + TDF + EFV<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>From Weeks 96 to 144 of the study, subjects received emtricitabine/tenofovir DF administered in combination with efavirenz in place of emtricitabine + tenofovir DF with efavirenz.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">30%</td>
<td class="Rrule" align="center">26%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (&gt;240 mg/dL)</td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">24%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990 U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alkaline Phosphatase (&gt;550 U/L)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hemoglobin (&lt;8.0 mg/dL)</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;250 mg/dL)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> (&gt;75 RBC/HPF)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span> (≥3+)</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Fasting Triglycerides (&gt;750 mg/dL)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
<p>Laboratory abnormalities observed in Study 073 were generally consistent with those in Study 934.</p>
<p>In addition to the laboratory abnormalities described for Study 934 (Table 3), Grade 3/4 elevations of bilirubin (&gt;2.5 × ULN), pancreatic amylase (&gt;2.0 × ULN), serum glucose (&lt;40 or &gt;250 mg/dL), and serum lipase (&gt;2.0 × ULN) occurred in up to 3% of subjects treated with emtricitabine or tenofovir DF with other antiretroviral agents in clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Hepatic Events:</span> In Study 934, 19 subjects treated with efavirenz, emtricitabine, and tenofovir DF and 20 subjects treated with efavirenz and fixed-dose zidovudine/lamivudine were <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">hepatitis B surface antigen</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C antibody positive. Among these coinfected subjects, one subject (1/19) in the efavirenz, emtricitabine and tenofovir DF arm had elevations in transaminases to greater than five times ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two subjects (2/20) had elevations in transaminases to greater than five times ULN through 144 weeks. No HBV and/or HCV coinfected subject discontinued from the study due to hepatobiliary disorders <span class="Italics">[See <a href="#S5.10">Warnings and Precautions (5.10)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.11"></a><p></p>
<h2>6.3	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of efavirenz, emtricitabine, or tenofovir DF. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p>
<p><span class="Underline">Ear and Labyrinth Disorders</span><br><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span></p>
<p><span class="Underline">General Disorders and Administration Site Conditions</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p>
<p><span class="Underline">Hepatobiliary Disorders</span><br>Hepatic enzyme increase, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></p>
<p><span class="Underline">Metabolism and Nutrition Disorders</span><br>Redistribution/accumulation of body fat <span class="Italics">[See <a href="#S5.14">Warnings and Precautions (5.14)</a>]</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span></p>
<p><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span><br>Abnormal coordination, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, cerebellar coordination and balance disturbances, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Underline">Psychiatric Disorders</span><br><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive reactions</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></p>
<p><span class="Underline">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span><br><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, photoallergic <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  No postmarketing adverse reactions have been identified for inclusion in this section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.14"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Underline">Metabolism and Nutrition Disorders</span><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span></p>
<p><span class="Underline">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, increased amylase, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Underline">Hepatobiliary Disorders</span><br><span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">Hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, increased liver enzymes (most commonly AST, ALT, gamma GT)</p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
<p><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (manifested as <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> </p>
<p><span class="Underline">Renal and Urinary Disorders</span><br><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, proximal renal tubulopathy, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (including acute cases), <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p>
<p><span class="Underline">General Disorders and Administration Site Conditions</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p>
<p>The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">This section describes clinically relevant drug interactions with ATRIPLA. Drug interaction studies are described elsewhere in the labeling [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Efavirenz</h2>
<p class="First">Efavirenz has been shown in vivo to induce CYP3A. Other compounds that are substrates of CYP3A may have decreased plasma concentrations when coadministered with efavirenz. In vitro studies have demonstrated that efavirenz inhibits CYP2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations. Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug. Therefore, appropriate dose adjustments may be necessary for these drugs.</p>
<p>Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Emtricitabine and Tenofovir Disoproxil Fumarate  </h2>
<p class="First">Since emtricitabine and tenofovir are primarily eliminated by the kidneys, coadministration of ATRIPLA with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of emtricitabine, tenofovir, and/or other renally eliminated drugs. Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, and valganciclovir.</p>
<p>Coadministration of tenofovir DF and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions [for didanosine dosing adjustment recommendations, see <span class="Italics"><a href="#table4">Table 4</a>]. </span>Suppression of CD4<span class="Sup">+</span> cell counts has been observed in patients receiving tenofovir DF with didanosine 400 mg daily. </p>
<p>Lopinavir/ritonavir has been shown to increase tenofovir concentrations. The mechanism of this interaction is unknown. Patients receiving lopinavir/ritonavir with ATRIPLA should be monitored for tenofovir-associated adverse reactions. ATRIPLA should be discontinued in patients who develop tenofovir-associated adverse reactions [<span class="Italics">See <a href="#table4">Table  4</a></span>].</p>
<p>Coadministration of atazanavir with ATRIPLA is not recommended since coadministration of atazanavir with either efavirenz or tenofovir DF has been shown to decrease plasma concentrations of atazanavir. Also, atazanavir has been shown to increase tenofovir concentrations. There are insufficient data to support dosing recommendations for atazanavir or atazanavir/ritonavir in combination with ATRIPLA  [<span class="Italics">See <a href="#table4">Table 4</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate   </h2>
<p class="First">Other important drug interaction information for ATRIPLA is summarized in Table 1 and Table 4. The drug interactions described are based on studies conducted with efavirenz, emtricitabine or tenofovir DF as individual agents or are potential drug interactions; no drug interaction studies have been conducted using ATRIPLA [for pharmacokinetics data see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>, Tables 5–9]. The tables include potentially significant interactions, but are not all inclusive. </p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4 Established and Other Potentially Significant<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Concomitant Drug  Class: Drug Name</th>
<th class="Rrule" align="center" valign="middle">Effect</th>
<th class="Rrule" align="center" valign="middle">Clinical Comment</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>This table is not all inclusive.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left" colspan="2"><span class="Italics">Antiretroviral agents</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  atazanavir</td>
<td class="Rrule" align="left">↓atazanavir concentration<br> ↑ tenofovir concentration</td>
<td class="Rrule" align="left">Coadministration of atazanavir with ATRIPLA is not recommended. Coadministration of atazanavir with either efavirenz or tenofovir DF decreases plasma concentrations of atazanavir. The combined effect of efavirenz plus tenofovir DF on atazanavir plasma concentrations is not known. Also, atazanavir has been shown to increase tenofovir concentrations. There are insufficient data to support dosing recommendations for atazanavir or atazanavir/ritonavir in combination with ATRIPLA. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  fosamprenavir calcium</td>
<td class="Rrule" align="left">↓ amprenavir concentration</td>
<td class="Rrule" align="left">Fosamprenavir (unboosted):  Appropriate doses of fosamprenavir and ATRIPLA with respect to safety and efficacy have not been established.<br> <br> Fosamprenavir/ritonavir:  An additional 100 mg/day (300 mg total) of ritonavir is recommended when ATRIPLA is administered with fosamprenavir/ritonavir once daily. No change in the ritonavir dose is required when ATRIPLA is administered with fosamprenavir plus ritonavir twice daily.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  indinavir</td>
<td class="Rrule" align="left">↓ indinavir concentration</td>
<td class="Rrule" align="left">The optimal dose of indinavir, when given in combination with efavirenz, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  lopinavir/ritonavir</td>
<td class="Rrule" align="left">↓ lopinavir concentration<br> ↑ tenofovir concentration</td>
<td class="Rrule" align="left">A dose increase of lopinavir/ritonavir to 600/150 mg (3 tablets) twice daily may be considered when used in combination with efavirenz in treatment-experienced patients where decreased susceptibility to lopinavir is clinically suspected (by treatment history or laboratory evidence). <span class="Bold">Patients should be monitored for tenofovir-associated adverse reactions. ATRIPLA should be discontinued in patients who develop tenofovir-associated adverse reactions</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  ritonavir</td>
<td class="Rrule" align="left">↑ ritonavir concentration<br> ↑ efavirenz concentration</td>
<td class="Rrule" align="left">When ritonavir 500 mg every 12 hours was coadministered with efavirenz 600 mg once daily, the combination was associated with a higher frequency of adverse clinical experiences (e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>) and laboratory abnormalities (elevated liver enzymes). Monitoring of liver enzymes is recommended when ATRIPLA is used in combination with ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Protease inhibitor:<br>  saquinavir</td>
<td class="Rrule" align="left">↓ saquinavir concentration</td>
<td class="Rrule" align="left">Should not be used as sole protease inhibitor in combination with ATRIPLA.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">NRTI:<br>  didanosine</td>
<td class="Rrule" align="left">↑ didanosine concentration</td>
<td class="Rrule" align="left">Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>. <span class="Bold">In adults weighing &gt;60 kg, the didanosine dose should be reduced to 250 mg if coadministered with ATRIPLA</span>. <span class="Bold">Data are not available to recommend a dose adjustment of didanosine for patients weighing &lt;60 kg. Coadministration of ATRIPLA and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. For additional information, please consult the Videx / Videx EC (didanosine) prescribing information.</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" colspan="2"><span class="Italics">Other agents</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticoagulant:<br>  warfarin</td>
<td class="Rrule" align="left">↑ or ↓ warfarin concentration</td>
<td class="Rrule" align="left">Plasma concentrations and effects potentially increased or decreased by efavirenz.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Anticonvulsants:<br>  carbamazepine</td>
<td class="Rrule" align="left">↓ carbamazepine concentration<br> ↓ efavirenz concentration</td>
<td class="Rrule" align="left">There are insufficient data to make a dose recommendation for ATRIPLA. Alternative anticonvulsant treatment should be used.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  phenytoin<br>  phenobarbital</td>
<td class="Rrule" align="left">↓ anticonvulsant concentration<br> ↓ efavirenz concentration</td>
<td class="Rrule" align="left">Potential for reduction in anticonvulsant and/or efavirenz plasma levels; periodic monitoring of anticonvulsant plasma levels should be conducted.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antidepressant:<br>  sertraline</td>
<td class="Rrule" align="left">↓ sertraline concentration</td>
<td class="Rrule" align="left">Increases in sertraline dose should be guided by clinical response.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Antifungals:<br>  itraconazole</td>
<td class="Rrule" align="left">↓ itraconazole concentration<br> ↓ hydroxy-itraconazole concentration</td>
<td class="Rrule" align="left">Since no dose recommendation for itraconazole can be made, alternative antifungal treatment should be considered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ketoconazole</td>
<td class="Rrule" align="left">↓ ketoconazole concentration</td>
<td class="Rrule" align="left">Drug interaction studies with ATRIPLA and ketoconazole have not been conducted. Efavirenz has the potential to decrease plasma concentrations of ketoconazole.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anti-infective:<br>  clarithromycin</td>
<td class="Rrule" align="left">↓ clarithromycin concentration<br> ↑ 14-OH metabolite concentration</td>
<td class="Rrule" align="left">Clinical significance unknown. In uninfected volunteers, 46% developed <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> while receiving efavirenz and clarithromycin. No dose adjustment of ATRIPLA is recommended when given with clarithromycin. Alternatives to clarithromycin, such as azithromycin, should be considered. Other macrolide antibiotics, such as erythromycin, have not been studied in combination with ATRIPLA.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimycobacterial:<br>  rifabutin</td>
<td class="Rrule" align="left">↓ rifabutin concentration</td>
<td class="Rrule" align="left">Increase daily dose of rifabutin by 50%. Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimycobacterial:<br>  rifampin</td>
<td class="Rrule" align="left">↓ efavirenz<br>concentration</td>
<td class="Rrule" align="left">Clinical significance of reduced efavirenz concentration is unknown. Dosing recommendations for concomitant use of ATRIPLA and rifampin have not been established.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Calcium channel blockers:<br>  diltiazem</td>
<td class="Rrule" align="left">↓ diltiazem concentration<br> ↓ desacetyl diltiazem concentration<br> ↓ N-monodes-methyl diltiazem concentration</td>
<td class="Rrule" align="left">Diltiazem dose adjustments should be guided by clinical response (refer to the prescribing information for diltiazem). No dose adjustment of ATRIPLA is necessary when administered with diltiazem.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Others (e.g., felodipine, nicardipine, nifedipine, verapamil)</td>
<td class="Rrule" align="left">↓ calcium channel blocker</td>
<td class="Rrule" align="left">No data are available on the potential interactions of efavirenz with other calcium channel blockers that are substrates of CYP3A. The potential exists for reduction in plasma concentrations of the calcium channel blocker. Dose adjustments should be guided by clinical response (refer to the prescribing information for the calcium channel blocker).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HMG-CoA reductase inhibitors:<br>  atorvastatin<br>  pravastatin<br>  simvastatin</td>
<td class="Rrule" align="left">↓ atorvastatin concentration<br> ↓ pravastatin concentration<br> ↓ simvastatin concentration</td>
<td class="Rrule" align="left">Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased with efavirenz. Consult the prescribing information for the HMG-CoA reductase inhibitor for guidance on individualizing the dose.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Hormonal contraceptives:</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral:<br>  Ethinyl<br>  estradiol/Norgestimate</td>
<td class="Rrule" align="left">↓ active metabolites of norgestimate</td>
<td class="Rrule" align="left">A reliable method of barrier contraception must be used in addition to hormonal contraceptives. Efavirenz had no effect on ethinyl estradiol concentrations, but progestin levels (norelgestromin and levonorgestrel) were markedly decreased. No effect of ethinyl estradiol/norgestimate on efavirenz plasma concentrations was observed. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Implant:<br>  Etonogestrel</td>
<td class="Rrule" align="left">↓ etonogestrel</td>
<td class="Rrule" align="left">A reliable method of barrier contraception must be used in addition to hormonal contraceptives. The interaction between etonogestrel and efavirenz has not been studied. Decreased exposure of etonogestrel may be expected. There have been postmarketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Immunosuppressants:<br>  Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A</td>
<td class="Rrule" align="left">↓ immuno-suppressant</td>
<td class="Rrule" align="left">Decreased exposure of the immunosuppressant may be expected due to CYP3A induction by efavirenz. These immunosuppressants are not anticipated to affect exposure of efavirenz. Dose adjustments of the immunosuppressant may be required. Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with ATRIPLA.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Narcotic analgesic:<br>  methadone</td>
<td class="Rrule" align="left">↓ methadone concentration</td>
<td class="Rrule" align="left">Coadministration of efavirenz in HIV-1 infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal. Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms. Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Efavirenz Assay Interference</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2></h2>
<p class="First">Cannabinoid Test Interaction:  Efavirenz does not bind to cannabinoid receptors. False-positive urine cannabinoid test results have been observed in non-HIV-infected volunteers receiving efavirenz when the Microgenics Cedia DAU Multi-Level THC assay was used for screening. Negative results were obtained when more specific confirmatory testing was performed with gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry. For more information, please consult the SUSTIVA prescribing information.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 	Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics">[See <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV-1. </span>Studies in rats have demonstrated that both efavirenz and tenofovir are secreted in milk. It is not known whether efavirenz, emtricitabine, or tenofovir is excreted in human milk. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are receiving ATRIPLA.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">ATRIPLA is not recommended for patients less than 18 years of age because it is a fixed-dose combination tablet containing a component, tenofovir DF, for which safety and efficacy have not been established in this age group.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of efavirenz, emtricitabine, or tenofovir DF did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for the elderly patients should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of efavirenz have not been adequately studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical experience in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, caution should be exercised in administering ATRIPLA to these patients <span class="Italics">[See <a href="#S5.10">Warnings and Precautions (5.10)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Because ATRIPLA is a fixed-dose combination, it should not be prescribed for patients requiring dosage adjustment such as those with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;50 mL/min) <span class="Italics">[See <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored for evidence of toxicity, including monitoring of vital signs and observation of the patient's clinical status; standard supportive treatment should then be applied as necessary. Administration of activated charcoal may be used to aid removal of unabsorbed efavirenz. Hemodialysis can remove both emtricitabine and tenofovir DF (refer to detailed information below), but is unlikely to significantly remove efavirenz from the blood.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Limited clinical experience is available at doses higher than the therapeutic dose of emtricitabine. In one clinical pharmacology study single doses of emtricitabine 1200 mg were administered to 11 subjects. No severe adverse reactions were reported.</p>
<p>Hemodialysis treatment removes approximately 30% of the emtricitabine dose over a 3-hour dialysis period starting within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether emtricitabine can be removed by peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Limited clinical experience at doses higher than the therapeutic dose of tenofovir DF 300 mg is available. In one study, 600 mg tenofovir DF was administered to 8 subjects orally for 28 days, and no severe adverse reactions were reported. The effects of higher doses are not known.</p>
<p>Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of tenofovir DF, a 4-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">ATRIPLA is a fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF). SUSTIVA is the brand name for efavirenz, a non-nucleoside reverse transcriptase inhibitor. EMTRIVA is the brand name for emtricitabine, a synthetic nucleoside analog of cytidine. VIREAD is the brand name for tenofovir DF, which is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. VIREAD and EMTRIVA are the components of TRUVADA.</p>
<p>ATRIPLA tablets are for oral administration. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir DF (which is equivalent to 245 mg of tenofovir disoproxil) as active ingredients. The tablets include the following inactive ingredients:  croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablets are film-coated with a coating material containing black iron oxide, polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, and titanium dioxide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Efavirenz is chemically described as (<span class="Italics">S</span>)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2<span class="Italics">H</span>-3,1-benzoxazin-2-one. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">9</span>ClF<span class="Sub">3</span>NO<span class="Sub">2</span> and its structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=076da359-b3d0-44f7-8c0e-662f5b7a8668&amp;name=atripla-01.jpg"></p>
<p>Efavirenz is a white to slightly pink crystalline powder with a molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 315.68. It is practically insoluble in water (&lt;10 µg/mL).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span> The chemical name of emtricitabine is 5-fluoro-1-(2<span class="Italics">R</span>,5<span class="Italics">S</span>)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.</p>
<p>It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">10</span>FN<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 247.24. It has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=076da359-b3d0-44f7-8c0e-662f5b7a8668&amp;name=atripla-02.jpg"></p>
<p>Emtricitabine is a white to off-white crystalline powder with a solubility of approximately 112 mg/mL in water at 25 <span class="Sup">o</span>C.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Tenofovir DF is a fumaric acid salt of the <span class="Italics">bis</span>-isopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of tenofovir disoproxil fumarate is 9-[(<span class="Italics">R</span>)-2[[bis[[(isopropoxycarbonyl)oxy]- methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">30</span>N<span class="Sub">5</span>O<span class="Sub">10</span>P • C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and a molecular weight of 635.52. It has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=076da359-b3d0-44f7-8c0e-662f5b7a8668&amp;name=atripla-03.jpg"></p>
<p>Tenofovir DF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25 °C.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<p class="First">For additional information on Mechanism of Action, Antiviral Activity, Resistance and Cross Resistance, please consult the SUSTIVA, EMTRIVA and VIREAD prescribing information.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">ATRIPLA is a fixed-dose combination of antiviral drugs efavirenz, emtricitabine and tenofovir disoproxil fumarate. <span class="Italics">[See <a href="#S12.4">Clinical Pharmacology (12.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">ATRIPLA:</span>  One ATRIPLA tablet is bioequivalent to one SUSTIVA tablet (600 mg) plus one EMTRIVA capsule (200 mg) plus one VIREAD tablet (300 mg) following single-dose administration to fasting healthy subjects (N=45).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  In HIV-1 infected subjects time-to-peak plasma concentrations were approximately 3–5 hours and steady-state plasma concentrations were reached in 6–10 days. In 35 HIV-1 infected subjects receiving efavirenz 600 mg once daily, steady-state C<span class="Sub">max</span> was 12.9 ± 3.7 µM (mean ± SD), C<span class="Sub">min</span> was 5.6 ± 3.2 μM, and AUC was 184 ± 73 µM∙hr. Efavirenz is highly bound (approximately 99.5–99.75%) to human plasma proteins, predominantly albumin. Following administration of <span class="Sup">14</span>C-labeled efavirenz, 14–34% of the dose was recovered in the urine (mostly as metabolites) and 16–61% was recovered in feces (mostly as parent drug). In vitro studies suggest CYP3A and CYP2B6 are the major isozymes responsible for efavirenz metabolism. Efavirenz has been shown to induce CYP enzymes, resulting in induction of its own metabolism. Efavirenz has a terminal half-life of 52–76 hours after single doses and 40–55 hours after multiple doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Following oral administration, emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1–2 hours post-dose. Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the steady-state plasma emtricitabine C<span class="Sub">max</span> was 1.8 ± 0.7 µg/mL (mean ± SD) and the AUC over a 24-hour dosing interval was 10.0 ± 3.1 µg∙hr/mL. The mean steady state plasma trough concentration at 24 hours post-dose was 0.09 µg/mL. The mean absolute bioavailability of emtricitabine was 93%. In vitro binding of emtricitabine to human plasma proteins is &lt;4% and is independent of concentration over the range of 0.02–200 µg/mL. Following administration of radiolabelled emtricitabine, approximately 86% is recovered in the urine and 13% is recovered as metabolites. The metabolites of emtricitabine include 3'-sulfoxide diastereomers and their glucuronic acid conjugate. Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with normal renal function of 213 ± 89 mL/min (mean ± SD). Following a single oral dose, the plasma emtricitabine half-life is approximately 10 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Following oral administration of a single 300 mg dose of tenofovir DF to HIV-1 infected subjects in the fasted state, maximum serum concentrations (C<span class="Sub">max</span>) were achieved in 1.0 ± 0.4 hrs (mean ± SD) and C<span class="Sub">max</span> and AUC values were 296 ± 90 ng/mL and 2287 ± 685 ng•hr/mL, respectively. The oral bioavailability of tenofovir from tenofovir DF in fasted subjects is approximately 25%. In vitro binding of tenofovir to human plasma proteins is &lt;0.7% and is independent of concentration over the range of 0.01–25 μg/mL. Approximately 70–80% of the intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with normal renal function of 243 ± 33 mL/min (mean ± SD). Following a single oral dose, the terminal elimination half-life of tenofovir is approximately 17 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Effects of Food on Oral Absorption</span></p>
<p>ATRIPLA has not been evaluated in the presence of food. Administration of efavirenz tablets with a high fat meal increased the mean AUC and C<span class="Sub">max </span>of efavirenz by 28% and 79%, respectively, compared to administration in the fasted state. Compared to fasted administration, dosing of tenofovir DF and emtricitabine in combination with either a high fat meal or a light meal increased the mean AUC and C<span class="Sub">max</span> of tenofovir by 35% and 15%, respectively, without affecting emtricitabine exposures <span class="Italics">[See <a href="#S2">Dosage and Administration (2)</a> and <a href="#S17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Race</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span> The pharmacokinetics of efavirenz in HIV-1 infected subjects appear to be similar among the racial groups studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.11"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span> No pharmacokinetic differences due to race have been identified following the administration of emtricitabine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations following the administration of tenofovir DF.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Gender</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.14"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate:</span>  Efavirenz, emtricitabine, and tenofovir pharmacokinetics are similar in male and female subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.15"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Pediatric and Geriatric Patients</span></p>
<p>Pharmacokinetic studies of tenofovir DF have not been performed in pediatric subjects (&lt;18 years). Efavirenz has not been studied in pediatric subjects below 3 years of age or who weigh less than 13 kg. Emtricitabine has been studied in pediatric subjects from 3 months to 17 years of age. ATRIPLA is not recommended for pediatric administration. Pharmacokinetics of efavirenz, emtricitabine and tenofovir have not been fully evaluated in the elderly (&gt;65 years) <span class="Italics">[See <a href="#S8">Use in Specific Populations (8)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.16"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.17"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  The pharmacokinetics of efavirenz have not been studied in subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; however, less than 1% of efavirenz is excreted unchanged in the urine, so the impact of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on efavirenz elimination should be minimal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.18"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  The pharmacokinetics of emtricitabine and tenofovir DF are altered in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In subjects with creatinine clearance &lt;50 mL/min, C<span class="Sub">max</span> and AUC<span class="Sub">0–</span><span class="Sub">∞</span> of emtricitabine and tenofovir were increased <span class="Italics">[See <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.19"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.20"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  The pharmacokinetics of efavirenz have not been adequately studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[See <a href="#S5.10">Warnings and Precautions (5.10)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.21"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  The pharmacokinetics of emtricitabine have not been studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; however, emtricitabine is not significantly metabolized by liver enzymes, so the impact of liver impairment should be limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.22"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  The pharmacokinetics of tenofovir following a 300 mg dose of tenofovir DF have been studied in non-HIV infected subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. There were no substantial alterations in tenofovir pharmacokinetics in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with unimpaired subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.23"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Assessment of Drug Interactions</span></p>
<p>The drug interaction studies described were conducted with efavirenz, emtricitabine, or tenofovir DF as individual agents; no drug interaction studies have been conducted using ATRIPLA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.24"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  The steady-state pharmacokinetics of efavirenz and tenofovir were unaffected when efavirenz and tenofovir DF were administered together versus each agent dosed alone. Specific drug interaction studies have not been performed with efavirenz and NRTIs other than tenofovir, lamivudine, and zidovudine. Clinically significant interactions would not be expected based on NRTIs elimination pathways.</p>
<p>Efavirenz has been shown in vivo to cause hepatic enzyme induction, thus increasing the biotransformation of some drugs metabolized by CYP3A. In vitro studies have shown that efavirenz inhibited CYP isozymes 2C9, 2C19, and 3A4 with K<span class="Sub">i</span> values (8.5–17 µM) in the range of observed efavirenz plasma concentrations. In in vitro studies, efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 (K<span class="Sub">i</span> values 82–160 µM) only at concentrations well above those achieved clinically. Coadministration of efavirenz with drugs primarily metabolized by 2C9, 2C19, and 3A4 isozymes may result in altered plasma concentrations of the coadministered drug. Drugs which induce CYP3A activity would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.</p>
<p>Drug interaction studies were performed with efavirenz and other drugs likely to be coadministered or drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>. There was no clinically significant interaction observed between efavirenz and zidovudine, lamivudine, azithromycin, fluconazole, lorazepam, cetirizine, or paroxetine. Single doses of famotidine or an aluminum and magnesium antacid with simethicone had no effects on efavirenz exposures. The effects of coadministration of efavirenz on C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> are summarized in Table 5 (effect of other drugs on efavirenz) and Table 6 (effect of efavirenz on other drugs). For information regarding clinical recommendations see <span class="Italics"><a href="#S7">Drug Interactions (7)</a>.</span></p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5 Drug Interactions:  Changes in Pharmacokinetic Parameters for Efavirenz in the Presence of the Coadministered Drug</span></caption>
<col align="left" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th align="center"></th>
<th align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="3">Mean % Change of Efavirenz Pharmacokinetic <br>  Parameters<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>  (90% CI)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Coadministered Drug</th>
<th class="Rrule" align="center">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center">Efavirenz Dose (mg)</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">NA = not available</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Increase = ↑; Decrease = ↓; No Effect = ↔</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Parallel-group design; N for efavirenz + lopinavir/ritonavir, N for efavirenz alone.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>95% CI</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Soft Gelatin Capsule</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>90% CI not available</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">#</a></dt>
<dd>Relative to steady-state administration of efavirenz (600 mg once daily for 9 days).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 mg q8h × 14 days</td>
<td class="Rrule" align="center">200 mg × 14 days</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/<br> ritonavir</td>
<td class="Rrule" align="center">400/100 mg q12h × 9 days</td>
<td class="Rrule" align="center">600 mg × 9 days</td>
<td class="Rrule" align="center">11, 12<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">↓ 16<br> (↓ 38 to  ↑ 15)</td>
<td class="Rrule" align="center">↓ 16<br> (↓ 42 to  ↑ 20)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Rrule" align="center">750 mg q8h × 7 days</td>
<td class="Rrule" align="center">600 mg × 7 days</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 32 to ↑ 13)<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 35 to  ↑ 18)<a href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">↓ 21<br> (↓ 53 to  ↑ 33)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center">500 mg q12h × 8 days</td>
<td class="Rrule" align="center">600 mg × 10 days</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">↑ 14<br> (↑ 4 to  ↑ 26)</td>
<td class="Rrule" align="center">↑ 21<br> (↑ 10 to  ↑ 34)</td>
<td class="Rrule" align="center">↑ 25<br> (↑ 7 to ↑ 46)<a href="#footnote-8" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir SGC<a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1200 mg q8h × 10 days</td>
<td class="Rrule" align="center">600 mg × 10 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↓ 13<br> (↓ 5 to ↓ 20)</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 4 to ↓ 19)</td>
<td class="Rrule" align="center">↓ 14<br> (↓ 2 to  ↓ 24)<a href="#footnote-8" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clarithromycin</td>
<td class="Rrule" align="center">500 mg q12h × 7 days</td>
<td class="Rrule" align="center">400 mg × 7 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↑ 11<br> (↑ 3 to  ↑ 19)</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Itraconazole</td>
<td class="Rrule" align="center">200 mg q12h × 14 days</td>
<td class="Rrule" align="center">600 mg × 28 days</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifabutin</td>
<td class="Rrule" align="center">300 mg qd × 14 days</td>
<td class="Rrule" align="center">600 mg × 14 days</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 24 to ↑ 1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifampin</td>
<td class="Rrule" align="center">600 mg × 7 days</td>
<td class="Rrule" align="center">600 mg × 7 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓ 20<br> (↓ 11 to  ↓ 28)</td>
<td class="Rrule" align="center">↓ 26<br> (↓ 15 to  ↓ 36)</td>
<td class="Rrule" align="center">↓ 32<br> (↓ 15 to  ↓ 46)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atorvastatin</td>
<td class="Rrule" align="center">10 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Pravastatin</td>
<td class="Rrule" align="center">40 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Simvastatin</td>
<td class="Rrule" align="center">40 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 28 to ↑ 8)</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">↓ 12<br> (↓ 25 to ↑ 3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Carbamazepine</td>
<td class="Rrule" align="center">200 mg qd × 3 days, 200 mg bid × 3 days, then 400 mg qd × 15 days</td>
<td class="Rrule" align="center">600 mg × 35 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓ 21<br> (↓ 15 to ↓ 26)</td>
<td class="Rrule" align="center">↓ 36<br> (↓ 32 to  ↓ 40)</td>
<td class="Rrule" align="center">↓ 47<br> (↓ 41 to  ↓ 53)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diltiazem</td>
<td class="Rrule" align="center">240 mg × 14 days </td>
<td class="Rrule" align="center">600 mg × 28 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↑ 16<br> (↑ 6 to ↑ 26)</td>
<td class="Rrule" align="center">↑ 11<br> (↑ 5 to ↑ 18)</td>
<td class="Rrule" align="center">↑ 13<br> (↑ 1 to ↑ 26)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sertraline</td>
<td class="Rrule" align="center">50 mg qd × 14 days</td>
<td class="Rrule" align="center">600 mg × 14 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↑ 11<br> (↑ 6 to ↑ 16)</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Voriconazole</td>
<td class="Rrule" align="center" valign="top">400 mg po q12h × 1 day then 200 mg po q12h × 8 days</td>
<td class="Rrule" align="center" valign="top">400 mg × 9 days</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↑ 38<a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a>
</td>
<td class="Rrule" align="center" valign="top">↑ 44<a href="#footnote-10" class="Sup">¶</a>
</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center" valign="top">300 mg po q12h days 2–7</td>
<td class="Rrule" align="center" valign="top">300 mg × 7 days </td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↓ 14<a name="footnote-reference-11" href="#footnote-11" class="Sup">#</a><br> (↓ 7 to ↓ 21) </td>
<td class="Rrule" align="center" valign="top">↔<a href="#footnote-11" class="Sup">#</a>
</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="top">400 mg po q12h days 2–7</td>
<td class="Rrule" align="center" valign="top">300 mg × 7 days</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↔<a href="#footnote-11" class="Sup">#</a>
</td>
<td class="Rrule" align="center" valign="top">↑ 17<a href="#footnote-11" class="Sup">#</a><br> (↑ 6 to ↑ 29)</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="100%">
<caption><span>Table 6 Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Efavirenz</span></caption>
<col align="left" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th align="center"></th>
<th align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="3">Mean % Change of Coadministered Drug Pharmacokinetic <br>  Parameters<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a>  (90% CI)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Coadministered Drug</th>
<th class="Rrule" align="center">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center">Efavirenz Dose (mg)</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">NA = not available</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Increase = ↑; Decrease = ↓; No Effect = ↔</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>Compared with atazanavir 400 mg qd alone.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">‡</a></dt>
<dd>Comparator dose of indinavir was 800 mg q8h × 10 days.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">§</a></dt>
<dd>Parallel-group design; N for efavirenz + lopinavir/ritonavir, N for lopinavir/ritonavir alone.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">¶</a></dt>
<dd>Values are for lopinavir. The pharmacokinetics of ritonavir 100 mg q12h are unaffected by concurrent efavirenz.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">#</a></dt>
<dd>95% CI</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">Þ</a></dt>
<dd>Soft Gelatin Capsule</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">ß</a></dt>
<dd>Not available because of insufficient data.</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">à</a></dt>
<dd>90% CI not available</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">è</a></dt>
<dd>Relative to steady-state administration of voriconazole (400 mg for 1 day, then 200 mg po q12h for 2 days).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top">Atazanavir</td>
<td class="Botrule Rrule" align="center">400 mg qd with a light meal d 1–20</td>
<td class="Botrule Rrule" align="center">600 mg qd with a light meal d 7–20</td>
<td class="Botrule Rrule" align="center">27</td>
<td class="Botrule Rrule" align="center">↓ 59<br> (↓ 49 to ↓ 67)</td>
<td class="Botrule Rrule" align="center">↓ 74<br> (↓ 68 to ↓ 78)</td>
<td class="Botrule Rrule" align="center">↓ 93<br> (↓ 90 to ↓ 95)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="center">400 mg qd d 1–6, then 300 mg qd d 7–20 with ritonavir 100 mg qd and a light meal</td>
<td class="Botrule Rrule" align="center">600 mg qd 2 h after atazanavir and ritonavir <br> d 7–20</td>
<td class="Botrule Rrule" align="center">13</td>
<td class="Botrule Rrule" align="center">↑ 14<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a><br> (↓ 17 to  ↑ 58)</td>
<td class="Botrule Rrule" align="center">↑ 39<a href="#footnote-13" class="Sup">†</a><br> (↑ 2 to  ↑ 88)</td>
<td class="Botrule Rrule" align="center">↑ 48<a href="#footnote-13" class="Sup">†</a><br> (↑ 24 to ↑ 76)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">300 mg qd/ritonavir 100 mg qd d 1–10 (pm), then 400 mg qd/ritonavir 100 mg qd d 11–24 (pm) (simultaneous with efavirenz)</td>
<td class="Rrule" align="center">600 mg qd with a light snack d 11–24 (pm)</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑ 17<br>(↑ 8 to ↑ 27)</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↓ 42<br>(↓ 31 to ↓ 51)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Botrule Rrule" align="center">1000 mg q8h × 10 days</td>
<td class="Botrule Rrule" align="center">600 mg × 10 days</td>
<td class="Botrule Rrule" align="center">20</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="2"></td>
<td class="Botrule Rrule" align="center" colspan="2">After morning dose</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"><p class="First">↔<a name="footnote-reference-14" href="#footnote-14" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center">↓ 33<a href="#footnote-14" class="Sup">‡</a><br> (↓ 26 to ↓ 39)</td>
<td class="Botrule Rrule" align="center">↓ 39<a href="#footnote-14" class="Sup">‡</a><br> (↓ 24 to ↓ 51)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center" colspan="2">After afternoon dose</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Rrule" align="center"><p class="First">↔<a href="#footnote-14" class="Sup">‡</a></p></td>
<td class="Rrule" align="center">↓ 37<a href="#footnote-14" class="Sup">‡</a><br> (↓ 26 to ↓ 46)</td>
<td class="Rrule" align="center">↓ 52<a href="#footnote-14" class="Sup">‡</a><br> (↓ 47 to ↓ 57)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center" colspan="2">After evening dose</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Rrule" align="center">↓ 29<a href="#footnote-14" class="Sup">‡</a><br> (↓ 11 to ↓ 43)</td>
<td class="Rrule" align="center">↓ 46<a href="#footnote-14" class="Sup">‡</a><br> (↓ 37 to ↓ 54)</td>
<td class="Rrule" align="center">↓ 57<a href="#footnote-14" class="Sup">‡</a><br> (↓ 50 to ↓ 63)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/<br> ritonavir</td>
<td class="Rrule" align="center">400/100 mg q12h × 9 days</td>
<td class="Rrule" align="center">600 mg × 9 days</td>
<td class="Rrule" align="center">11, 7<a name="footnote-reference-15" href="#footnote-15" class="Sup">§</a>
</td>
<td class="Rrule" align="center"><p class="First">↔<a name="footnote-reference-16" href="#footnote-16" class="Sup">¶</a></p></td>
<td class="Rrule" align="center">↓ 19<a href="#footnote-16" class="Sup">¶</a><br> (↓ 36 to ↑ 3)</td>
<td class="Rrule" align="center">↓ 39<a href="#footnote-16" class="Sup">¶</a><br> (↓ 3 to  ↓ 62)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Rrule" align="center">750 mg q8h × 7 days</td>
<td class="Rrule" align="center">600 mg × 7 days</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↑ 21<br> (↑ 10 to ↑ 33)</td>
<td class="Rrule" align="center">↑ 20 <br> (↑ 8 to  ↑ 34)</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metabolite<br> AG-1402</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↓ 40 <br> (↓ 30 to ↓ 48)</td>
<td class="Rrule" align="center">↓ 37<br> (↓ 25 to ↓ 48)</td>
<td class="Rrule" align="center">↓ 43<br> (↓ 21 to ↓ 59)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Botrule Rrule" align="center">500 mg q12h × 8 days</td>
<td class="Botrule Rrule" align="center">600 mg × 10 days</td>
<td class="Botrule Rrule" align="center">11</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="center" colspan="2">After AM dose</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center">↑ 24<br> (↑ 12 to  ↑ 38)</td>
<td class="Botrule Rrule" align="center">↑ 18<br> (↑ 6 to   ↑ 33)</td>
<td class="Botrule Rrule" align="center">↑ 42<br> (↑ 9 to ↑ 86)<a href="#footnote-17" class="Sup">#</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center" colspan="2">After PM dose</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↑ 24<br> (↑ 3 to ↑ 50)<a name="footnote-reference-17" href="#footnote-17" class="Sup">#</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir<br> SGC<a name="footnote-reference-18" href="#footnote-18" class="Sup">Þ</a>
</td>
<td class="Rrule" align="center">1200 mg q8h × 10 days</td>
<td class="Rrule" align="center">600 mg × 10 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓ 50<br> (↓ 28 to  ↓ 66)</td>
<td class="Rrule" align="center">↓ 62<br> (↓ 45 to  ↓ 74)</td>
<td class="Rrule" align="center">↓ 56<br> (↓ 16 to  ↓ 77)<a href="#footnote-17" class="Sup">#</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Clarithromycin</td>
<td class="Rrule" align="center">500 mg q12h × 7 days</td>
<td class="Rrule" align="center">400 mg × 7 days</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">↓ 26<br> (↓ 15 to  ↓ 35)</td>
<td class="Rrule" align="center">↓ 39<br> (↓ 30 to ↓ 46)</td>
<td class="Rrule" align="center">↓ 53<br> (↓ 42 to ↓ 63)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">14-OH metabolite</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↑ 49<br> (↑ 32 to  ↑ 69)</td>
<td class="Rrule" align="center">↑ 34<br> (↑ 18 to ↑ 53)</td>
<td class="Rrule" align="center">↑ 26<br> (↑ 9 to ↑ 45)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Itraconazole</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">200 mg q12h × 28 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">600 mg ×14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">18</td>
<td class="Rrule" align="center">↓ 37<br> (↓ 20 to  ↓ 51)</td>
<td class="Rrule" align="center">↓ 39<br> (↓ 21 to ↓ 53)</td>
<td class="Rrule" align="center">↓ 44<br> (↓ 27 to  ↓ 58)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="bottom">Hydroxy-itraconazole</td>
<td class="Rrule" align="center">↓ 35<br> (↓ 12 to  ↓ 52)</td>
<td class="Rrule" align="center">↓ 37<br> (↓ 14 to  ↓ 55)</td>
<td class="Rrule" align="center">↓ 43<br> (↓ 18 to  ↓ 60)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifabutin</td>
<td class="Rrule" align="center">300 mg qd × 14 days</td>
<td class="Rrule" align="center">600 mg × 14 days</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">↓ 32<br> (↓ 15 to ↓ 46)</td>
<td class="Rrule" align="center">↓ 38<br> (↓ 28 to ↓ 47)</td>
<td class="Rrule" align="center">↓ 45<br> (↓ 31 to ↓ 56)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Atorvastatin</td>
<td class="Rrule" align="center">10 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓ 14<br> (↓ 1 to ↓ 26)</td>
<td class="Rrule" align="center">↓ 43<br> (↓ 34 to ↓ 50)</td>
<td class="Rrule" align="center">↓ 69<br> (↓ 49 to ↓ 81)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total active (including metabolites)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↓ 15<br> (↓ 2 to ↓ 26)</td>
<td class="Rrule" align="center">↓ 32<br> (↓ 21 to ↓ 41)</td>
<td class="Rrule" align="center">↓ 48<br> (↓ 23 to ↓ 64)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Pravastatin</td>
<td class="Rrule" align="center">40 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↓ 32<br> (↓ 59 to ↑ 12)</td>
<td class="Rrule" align="center">↓ 44<br> (↓ 26 to ↓ 57)</td>
<td class="Rrule" align="center">↓ 19<br> (↓ 0 to ↓ 35)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Simvastatin</td>
<td class="Rrule" align="center">40 mg qd × 4 days</td>
<td class="Rrule" align="center">600 mg × 15 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓ 72<br> (↓ 63 to ↓ 79)</td>
<td class="Rrule" align="center">↓ 68<br> (↓ 62 to  ↓ 73)</td>
<td class="Rrule" align="center">↓ 45<br> (↓ 20 to ↓ 62)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total active (including metabolites)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↓ 68<br> (↓ 55 to ↓ 78)</td>
<td class="Rrule" align="center">↓ 60<br> (↓ 52 to ↓ 68)</td>
<td class="Rrule" align="center">
<br> NA<a name="footnote-reference-19" href="#footnote-19" class="Sup">ß</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Carbamazepine</td>
<td class="Rrule" align="center">200 mg qd × 3 days, 200 mg bid × 3 days, then 400 mg qd × 29 days</td>
<td class="Rrule" align="center">600 mg × 14 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓ 20<br> (↓ 15 to ↓ 24)</td>
<td class="Rrule" align="center">↓ 27<br> (↓ 20 to ↓ 33)</td>
<td class="Rrule" align="center">↓ 35<br> (↓ 24 to ↓ 44)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Epoxide metabolite</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↓ 13<br> (↓ 30 to ↑ 7)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diltiazem</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="top">240 mg × 21 days </td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="top">600 mg × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="top">13</td>
<td class="Rrule" align="center">↓ 60<br> (↓ 50 to ↓ 68)</td>
<td class="Rrule" align="center">↓ 69<br> (↓ 55 to ↓ 79)</td>
<td class="Rrule" align="center">↓ 63<br> (↓ 44 to  ↓ 75)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Desacetyl diltiazem</td>
<td class="Rrule" align="center">↓ 64<br> (↓ 57 to ↓ 69)</td>
<td class="Rrule" align="center">↓ 75<br> (↓ 59 to ↓ 84)</td>
<td class="Rrule" align="center">↓ 62<br> (↓ 44 to ↓ 75)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N-monodesmethyl diltiazem</td>
<td class="Rrule" align="center">↓ 28<br> (↓ 7 to ↓ 44)</td>
<td class="Rrule" align="center">↓ 37<br> (↓ 17 to ↓ 52)</td>
<td class="Rrule" align="center">↓ 37<br> (↓ 17 to ↓ 52)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Ethinyl estradiol/ Norgestimate</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">0.035 mg/0.25 mg × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">600 mg × 14 days</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Ethinyl estradiol</td>
<td class="Botrule Rrule" align="center">21</td>
<td class="Botrule Rrule" align="center">↔</td>
<td class="Botrule Rrule" align="center">↔</td>
<td class="Botrule Rrule" align="center">↔</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Norelgestromin</td>
<td class="Botrule Lrule Rrule" align="center">21</td>
<td class="Botrule Rrule" align="center">↓ 46<br>(↓39 to ↓ 52)</td>
<td class="Botrule Rrule" align="center">↓ 64<br>(↓ 62 to ↓ 67)</td>
<td class="Botrule Rrule" align="center">↓ 82<br>(↓ 79 to ↓ 85)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Levonorgestrel</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">↓ 80<br>(↓77 to ↓ 83)</td>
<td class="Rrule" align="center">↓ 83<br>(↓79 to ↓ 87)</td>
<td class="Rrule" align="center">↓ 86<br>(↓80 to ↓ 90)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methadone</td>
<td class="Rrule" align="center">Stable maintenance 35–100 mg daily</td>
<td class="Rrule" align="center">600 mg × <br> 14–21 days</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">↓ 45<br> (↓ 25 to ↓ 59)</td>
<td class="Rrule" align="center">↓ 52<br> (↓ 33 to ↓ 66)</td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sertraline</td>
<td class="Rrule" align="center">50 mg qd × 14 days</td>
<td class="Rrule" align="center">600 mg × 14 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↓ 29<br> (↓ 15 to  ↓ 40)</td>
<td class="Rrule" align="center">↓ 39<br> (↓ 27 to ↓ 50)</td>
<td class="Rrule" align="center">↓ 46<br> (↓ 31 to ↓ 58)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Voriconazole</td>
<td class="Rrule" align="center" valign="top">400 mg po q12h × 1 day then 200 mg po q12h × 8 days</td>
<td class="Rrule" align="center" valign="top">400 mg × 9 days<br><br>
</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↓ 61<a name="footnote-reference-20" href="#footnote-20" class="Sup">à</a>
</td>
<td class="Rrule" align="center" valign="top">↓ 77<a href="#footnote-20" class="Sup">à</a>
</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center" valign="top">300 mg po q12h days 2–7</td>
<td class="Rrule" align="center" valign="top">300 mg × 7 days</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↓ 36<a name="footnote-reference-21" href="#footnote-21" class="Sup">è</a><br> (↓ 21 to  ↓ 49)</td>
<td class="Rrule" align="center" valign="top">↓ 55<a href="#footnote-21" class="Sup">è</a><br> (↓ 45 to ↓ 62)</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="top">400 mg po q12h days 2–7</td>
<td class="Rrule" align="center" valign="top">300 mg × 7 days</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">↑ 23<a href="#footnote-21" class="Sup">è</a><br> (↓ 1 to  ↑ 53</td>
<td class="Rrule" align="center" valign="top">↓ 7<a href="#footnote-21" class="Sup">è</a><br>															 (↓ 23 to ↑ 13)</td>
<td class="Rrule" align="center" valign="top">NA</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.25"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  The steady-state pharmacokinetics of emtricitabine and tenofovir were unaffected when emtricitabine and tenofovir DF were administered together versus each agent dosed alone.</p>
<p>In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP mediated interactions involving emtricitabine and tenofovir with other medicinal products is low.</p>
<p>Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. No drug-drug interactions due to competition for renal excretion have been observed; however, coadministration of emtricitabine and tenofovir DF with drugs that are eliminated by active tubular secretion may increase concentrations of emtricitabine, tenofovir, and/or the coadministered drug.</p>
<p>Drugs that decrease renal function may increase concentrations of emtricitabine and/or tenofovir.</p>
<p>No clinically significant drug interactions have been observed between emtricitabine and famciclovir, indinavir, stavudine, tenofovir DF and zidovudine. Similarly, no clinically significant drug interactions have been observed between tenofovir DF and abacavir, efavirenz, emtricitabine, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirin, saquinavir/ritonavir or tacrolimus in studies conducted in healthy volunteers.</p>
<p>Following multiple dosing to HIV-negative subjects receiving either chronic methadone maintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state tenofovir pharmacokinetics were similar to those observed in previous studies, indicating a lack of clinically significant drug interactions between these agents and tenofovir DF.</p>
<p>The effects of coadministered drugs on the C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> of tenofovir are shown in Table 7. The effects of coadministration of tenofovir DF on C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> of coadministered drugs are shown in Table 8 and Table 9. </p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7 Drug Interactions:  Changes in Pharmacokinetic Parameters for Tenofovir in the Presence of the Coadministered Drug<a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-23" href="#footnote-23" class="Sup">†</a></span></caption>
<col align="left" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">Mean % Change of Tenofovir Pharmacokinetic Parameters<a name="footnote-reference-24" href="#footnote-24" class="Sup">‡</a><br> (90% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>All interaction studies conducted in healthy volunteers.</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">†</a></dt>
<dd>Subjects received tenofovir DF 300 mg once daily.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">‡</a></dt>
<dd>Increase = ↑; Decrease = ↓; No Effect = ↔</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">§</a></dt>
<dd>Reyataz Prescribing Information</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-25" href="#footnote-25" class="Sup">§</a>
</td>
<td class="Rrule" align="center">400 once daily<br> × 14 days</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">↑ 14<br>  (↑ 8 to ↑ 20)</td>
<td class="Rrule" align="center">↑ 24<br>  (↑ 21 to ↑ 28)</td>
<td class="Rrule" align="center">↑ 22<br>  (↑ 15 to ↑ 30)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (enteric-coated)</td>
<td class="Rrule" align="center">400 once</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (buffered)</td>
<td class="Rrule" align="center">250 or 400 once daily × 7 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Lopinavir/ ritonavir </td>
<td class="Rrule" align="center">400/100 twice daily × 14 days</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">↑ 32<br>  (↑ 25 to ↑ 38)</td>
<td class="Rrule" align="center">↑ 51<br>  (↑ 37 to ↑ 66)</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="80%">
<caption><span>Table 8 Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Tenofovir Disoproxil Fumarate<a name="footnote-reference-26" href="#footnote-26" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-27" href="#footnote-27" class="Sup">†</a></span></caption>
<col align="left" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">Mean % Change of Coadministered Drug Pharmacokinetic Parameters<a name="footnote-reference-28" href="#footnote-28" class="Sup">‡</a><br>  (90% CI)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-26" href="#footnote-reference-26">*</a></dt>
<dd>All interaction studies conducted in healthy volunteers.</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">†</a></dt>
<dd>Subjects received tenofovir DF 300 mg once daily.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">‡</a></dt>
<dd>Increase = ↑; Decrease = ↓; No Effect = ↔</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">§</a></dt>
<dd>Reyataz Prescribing Information</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">¶</a></dt>
<dd>In HIV-infected patients, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C<span class="Sub">min</span> values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-29" href="#footnote-29" class="Sup">§</a>
</td>
<td class="Botrule Rrule" align="center">400 once daily<br> × 14 days</td>
<td class="Botrule Rrule" align="center">34</td>
<td class="Botrule Rrule" align="center">↓ 21<br>  (↓ 27 to ↓ 14)</td>
<td class="Botrule Rrule" align="center">↓ 25<br>  (↓ 30 to ↓ 19)</td>
<td class="Botrule Rrule" align="center">↓ 40<br>  (↓ 48 to ↓ 32)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">Atazanavir/ritonavir<br> 300/100 once daily<br> × 42 days</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↓ 28<br>  (↓ 50 to ↑ 5)</td>
<td class="Rrule" align="center">↓ 25<a name="footnote-reference-30" href="#footnote-30" class="Sup">¶</a><br>  (↓ 42 to ↓ 3)</td>
<td class="Rrule" align="center">↓ 23<a href="#footnote-30" class="Sup">¶</a><br>  (↓ 46 to ↑ 10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir</td>
<td class="Rrule" align="center">Lopinavir/ritonavir 400/100 twice daily × 14 days</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center">Lopinavir/ritonavir 400/100 twice daily × 14 days</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
</tbody>
</table>
<p>Coadministration of tenofovir DF with didanosine results in changes in the pharmacokinetics of didanosine that may be of clinical significance. Table 9 summarizes the effects of tenofovir DF on the pharmacokinetics of didanosine. Concomitant dosing of tenofovir DF with didanosine buffered tablets or enteric-coated capsules significantly increases the C<span class="Sub">max</span> and AUC of didanosine. When didanosine 250 mg enteric-coated capsules were administered with tenofovir DF, systemic exposures of didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions. The mechanism of this interaction is unknown [for didanosine dosing adjustment recommendations see <span class="Italics"><a href="#S7.3">Drug Interactions (7.3)</a></span>, Table 4].</p>
<a name="table9"></a><table width="80%">
<caption><span>Table 9 Drug Interactions:  Changes in Pharmacokinetic Parameters for Didanosine in the Presence of Tenofovir Disoproxil Fumarate<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-32" href="#footnote-32" class="Sup">†</a></span></caption>
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Didanosine Dose (mg)/Method of Administration<a name="footnote-reference-33" href="#footnote-33" class="Sup">‡</a>
</th>
<th class="Rrule" align="center" rowspan="2">Tenofovir DF Method of Administration<a href="#footnote-32" class="Sup">†</a><span class="Sup">,</span><a href="#footnote-33" class="Sup">‡</a>
</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="2">Mean % Change (90% CI) vs. Didanosine  400 mg Alone, Fasted<a name="footnote-reference-34" href="#footnote-34" class="Sup">§</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>All interaction studies conducted in healthy volunteers.</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">†</a></dt>
<dd>Subjects received tenofovir DF 300 mg once daily.</dd>
<dt><a name="footnote-33" href="#footnote-reference-33">‡</a></dt>
<dd>Administration with food was with a light meal (~373 kcal, 20% fat).</dd>
<dt><a name="footnote-34" href="#footnote-reference-34">§</a></dt>
<dd>Increase = ↑; Decrease = ↓; No Effect = ↔</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">¶</a></dt>
<dd>Includes 4 subjects weighing &lt;60 kg receiving ddI 250 mg.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left" colspan="2"><span class="Bold">Buffered tablets</span></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once daily<a name="footnote-reference-35" href="#footnote-35" class="Sup">¶</a> × 7 days</td>
<td class="Rrule" align="center">Fasted 1 hour after didanosine</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑ 28<br>  (↑ 11 to ↑ 48)</td>
<td class="Rrule" align="center">↑ 44<br>  (↑ 31 to ↑ 59)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" colspan="2"><span class="Bold">Enteric coated capsules</span></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, fasted</td>
<td class="Rrule" align="center">With food, 2 hr after didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 48<br>  (↑ 25 to ↑ 76)</td>
<td class="Rrule" align="center">↑ 48<br> (↑ 31 to ↑ 67)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, with food</td>
<td class="Rrule" align="center">Simultaneously with didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 64<br>  (↑ 41 to ↑ 89)</td>
<td class="Rrule" align="center">↑ 60<br>  (↑ 44 to ↑ 79)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="center">With food, 2 hr after didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">↓ 10<br>  (↓ 22 to ↑ 3)</td>
<td class="Rrule" align="center">																↔ 															</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="center">Simultaneously with didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">																↔ 															</td>
<td class="Rrule" align="center">↑ 14<br>  (0 to ↑ 31)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">250 once, with food</td>
<td class="Rrule" align="center">Simultaneously with didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">↓ 29<br>  (↓ 39 to ↓ 18)</td>
<td class="Rrule" align="center">↓ 11<br>  (↓ 23 to ↑ 2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.26"></a><p></p>
<h2>12.4	Microbiology</h2>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.27"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Mechanism of Action</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.28"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase (RT). HIV-2 RT and human cellular DNA polymerases α, β, γ, and δ are not inhibited by efavirenz.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.29"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.  Emtricitabine 5'-triphosphate is a weak inhibitor of mammalian DNA polymerase α, β, ε, and mitochondrial DNA polymerase γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.30"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Tenofovir DF is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir DF requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.31"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiviral Activity</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.32"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate:</span>  In combination studies evaluating the antiviral activity in cell culture of emtricitabine and efavirenz together, efavirenz and tenofovir together, and emtricitabine and tenofovir together, additive to synergistic antiviral effects were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.33"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  The concentration of efavirenz inhibiting replication of wild-type laboratory adapted <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates in cell culture by 90–95% (EC<span class="Sub">90–95</span>) ranged from 1.7–25 nM in lymphoblastoid cell lines, peripheral blood mononuclear cells, and macrophage/monocyte cultures. Efavirenz demonstrated additive antiviral activity against HIV-1 in cell culture when combined with non-nucleoside reverse transcriptase inhibitors (NNRTIs) (delavirdine and nevirapine), nucleoside reverse transcriptase inhibitors (NRTIs) (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine), protease inhibitors (PIs) (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), and the fusion inhibitor enfuvirtide. Efavirenz demonstrated additive to antagonistic antiviral activity in cell culture with atazanavir. Efavirenz demonstrated antiviral activity against clade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N), but had reduced antiviral activity against group O viruses. Efavirenz is not active against HIV-2.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.34"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  The antiviral activity in cell culture of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells. The 50% effective concentration (EC<span class="Sub">50</span>) values for emtricitabine were in the range of 0.0013–0.64 µM (0.0003–0.158 µg/mL). In drug combination studies of emtricitabine with NRTIs (abacavir, lamivudine, stavudine, zalcitabine, and zidovudine), NNRTIs (delavirdine, efavirenz, and nevirapine), and PIs (amprenavir, nelfinavir, ritonavir, and saquinavir), additive to synergistic effects were observed. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC<span class="Sub">50</span> values ranged from 0.007–0.075 µM) and showed <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific activity against HIV-2 (EC<span class="Sub">50</span> values ranged from 0.007–1.5 µM).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.35"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  The antiviral activity in cell culture of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The EC<span class="Sub">50</span> values for tenofovir were in the range of 0.04–8.5 µM. In drug combination studies of tenofovir with NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine), NNRTIs (delavirdine, efavirenz, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G and O (EC<span class="Sub">50</span> values ranged from 0.5–2.2 µM) and showed <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific activity against HIV-2 (EC<span class="Sub">50</span> values ranged from 1.6 µM to 5.5 µM).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.36"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Resistance</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.37"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate:</span> HIV-1 isolates with reduced susceptibility to the combination of emtricitabine and tenofovir have been selected in cell culture and in clinical studies. Genotypic analysis of these isolates identified the M184V/I and/or K65R amino acid substitutions in the viral RT.</p>
<p>In a clinical study of treatment-naive subjects <span class="Italics">[Study 934, </span>see <span class="Italics"><a href="#S14">Clinical Studies (14)</a>]</span> resistance analysis was performed on HIV-1 isolates from all confirmed virologic failure subjects with &gt;400 copies/mL of HIV-1 RNA at Week 144 or early discontinuations. Genotypic resistance to efavirenz, predominantly the K103N substitution, was the most common form of resistance that developed. Resistance to efavirenz occurred in 13/19 analyzed subjects in the emtricitabine + tenofovir DF group and in 21/29 analyzed subjects in the zidovudine/lamivudine fixed-dose combination group. The M184V amino acid substitution, associated with resistance to emtricitabine and lamivudine, was observed in 2/19 analyzed subject isolates in the emtricitabine + tenofovir DF group and in 10/29 analyzed subject isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.</p>
<p>In a clinical study of treatment-naive subjects, isolates from 8/47 (17%) analyzed subjects receiving tenofovir DF developed the K65R substitution through 144 weeks of therapy; 7 of these occurred in the first 48 weeks of treatment and one at Week 96. In treatment experienced subjects, 14/304 (5%) of tenofovir DF treated subjects with virologic failure through Week 96 showed &gt;1.4 fold (median 2.7) reduced susceptibility to tenofovir. Genotypic analysis of the resistant isolates showed a substitution in the HIV-1 RT gene resulting in the K65R amino acid substitution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.38"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz: </span> Clinical isolates with reduced susceptibility in cell culture to efavirenz have been obtained. The most frequently observed amino acid substitution in clinical studies with efavirenz is K103N (54%). One or more RT substitutions at amino acid positions 98, 100, 101, 103, 106, 108, 188, 190, 225, 227, and 230 were observed in subjects failing treatment with efavirenz in combination with other antiretrovirals. Other resistance substitutions observed to emerge commonly included L100I (7%), K101E/Q/R (14%), V108I (11%), G190S/T/A (7%), P225H (18%), and M230I/L (11%).</p>
<p>HIV-1 isolates with reduced susceptibility to efavirenz (&gt;380-fold increase in EC<span class="Sub">90</span> value) emerged rapidly under selection in cell culture. Genotypic characterization of these viruses identified substitutions resulting in single amino acid substitutions L100I or V179D, double substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in RT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.39"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Emtricitabine-resistant isolates of HIV-1 have been selected in cell culture and in clinical studies. Genotypic analysis of these isolates showed that the reduced susceptibility to emtricitabine was associated with a substitution in the HIV-1 RT gene at codon 184 which resulted in an amino acid substitution of methionine by valine or isoleucine (M184V/I).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.40"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  HIV-1 isolates with reduced susceptibility to tenofovir have been selected in cell culture. These viruses expressed a K65R substitution in RT and showed a 2–4 fold reduction in susceptibility to tenofovir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.41"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Cross Resistance</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.42"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate:</span> Cross-resistance has been recognized among NNRTIs. Cross resistance has also been recognized among certain NRTIs. The M184V/I and/or K65R substitutions selected in cell culture by the combination of emtricitabine and tenofovir are also observed in some HIV-1 isolates from subjects failing treatment with tenofovir in combination with either lamivudine or emtricitabine, and either abacavir or didanosine. Therefore, cross-resistance among these drugs may occur in patients whose virus harbors either or both of these amino acid substitutions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.43"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Clinical isolates previously characterized as efavirenz-resistant were also phenotypically resistant in cell culture to delavirdine and nevirapine compared to baseline. Delavirdine- and/or nevirapine-resistant clinical viral isolates with NNRTI resistance-associated substitutions (A98G, L100I, K101E/P, K103N/S, V106A, Y181X, Y188X, G190X, P225H, F227L, or M230L) showed reduced susceptibility to efavirenz in cell culture. Greater than 90% of NRTI-resistant isolates tested in cell culture retained susceptibility to efavirenz.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.44"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Emtricitabine-resistant isolates (M184V/I) were cross-resistant to lamivudine and zalcitabine but retained susceptibility in cell culture to didanosine, stavudine, tenofovir, zidovudine, and NNRTIs (delavirdine, efavirenz, and nevirapine). HIV-1 isolates containing the K65R substitution, selected in vivo by abacavir, didanosine, tenofovir, and zalcitabine, demonstrated reduced susceptibility to inhibition by emtricitabine. Viruses harboring substitutions conferring reduced susceptibility to stavudine and zidovudine (M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E) or didanosine (L74V) remained sensitive to emtricitabine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.45"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  The K65R substitution selected by tenofovir is also selected in some HIV-1 infected patients treated with abacavir, didanosine, or zalcitabine. HIV-1 isolates with the K65R substitution also showed reduced susceptibility to emtricitabine and lamivudine. Therefore, cross-resistance among these drugs may occur in patients whose virus harbors the K65R substitution. HIV-1 isolates from patients (N=20) whose HIV-1 expressed a mean of 3 zidovudine-associated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir. Subjects whose virus expressed an L74V substitution without zidovudine resistance associated substitutions (N=8) had reduced response to VIREAD. Limited data are available for patients whose virus expressed a Y115F substitution (N=3), Q151M substitution (N=2), or T69 insertion (N=4), all of whom had a reduced response.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Long-term carcinogenicity studies in mice and rats were carried out with efavirenz. Mice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas and pulmonary alveolar/bronchiolar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased above background in females. No increases in tumor incidence above background were seen in males. In studies in which rats were administered efavirenz at doses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence above background were observed. The systemic exposure (based on AUCs) in mice was approximately 1.7-fold that in humans receiving the 600-mg/day dose. The exposure in rats was lower than that in humans. The mechanism of the carcinogenic potential is unknown. However, in genetic toxicology assays, efavirenz showed no evidence of mutagenic or clastogenic activity in a battery of in vitro and in vivo studies. These included bacterial mutation assays in <span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli</span>, mammalian mutation assays in Chinese hamster ovary cells, chromosome aberration assays in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or Chinese hamster ovary cells, and an in vivo mouse bone marrow micronucleus assay. Given the lack of genotoxic activity of efavirenz, the relevance to humans of neoplasms in efavirenz-treated mice is not known.</p>
<p>Efavirenz did not impair mating or fertility of male or female rats, and did not affect sperm of treated male rats. The reproductive performance of offspring born to female rats given efavirenz was not affected. As a result of the rapid clearance of efavirenz in rats, systemic drug exposures achieved in these studies were equivalent to or below those achieved in humans given therapeutic doses of efavirenz.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  In long-term carcinogenicity studies of emtricitabine, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/day (31 times the human systemic exposure at the therapeutic dose).</p>
<p>Emtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test), mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> or mouse micronucleus assays.</p>
<p>Emtricitabine did not affect fertility in male rats at approximately 140-fold or in male and female mice at approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily dose. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended 200 mg daily dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Long-term oral carcinogenicity studies of tenofovir DF in mice and rats were carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in humans at the therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. At the high dose in female mice, liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased at exposures 16 times that in humans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.</p>
<p>Tenofovir DF was mutagenic in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and negative in an in vitro bacterial mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, tenofovir DF was negative when administered to male mice.</p>
<p>There were no effects on fertility, mating performance or early embryonic development when tenofovir DF was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating through day seven of gestation. There was, however, an alteration of the estrous cycle in female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.5"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Efavirenz:</span>  Nonsustained <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> were observed in 6 of 20 monkeys receiving efavirenz at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate: </span>Tenofovir and tenofovir DF administered in toxicology studies to rats, dogs and monkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>. <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">Osteomalacia</span> observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown.</p>
<p>Evidence of renal toxicity was noted in 4 animal species administered tenofovir and tenofovir DF. Increases in serum creatinine, BUN, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, phosphaturia and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2–20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">Clinical Study 934 supports the use of ATRIPLA tablets in antiretroviral treatment-naïve HIV-1 infected patients. Additional data in support of the use of ATRIPLA in treatment- naive patients can be found in the prescribing information for VIREAD.</p>
<p>Clinical Study 073 provides clinical experience in subjects with stable, virologic suppression and no history of virologic failure who switched from their current regimen to ATRIPLA.</p>
<p>In antiretroviral treatment-experienced patients, the use of ATRIPLA tablets may be considered for patients with HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> that are expected to be susceptible to the components of ATRIPLA as assessed by treatment history or by genotypic or phenotypic testing <span class="Italics">[See <a href="#S12.4">Clinical Pharmacology (12.4)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 934:</span>  Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled multicenter study comparing emtricitabine + tenofovir DF administered in combination with efavirenz versus zidovudine/lamivudine fixed-dose combination administered in combination with efavirenz in 511 antiretroviral-naive subjects. From weeks 96 to 144 of the study, subjects received emtricitabine/tenofovir DF fixed-dose combination with efavirenz in place of emtricitabine + tenofovir DF with efavirenz. Subjects had a mean age of 38 years (range 18–80), 86% were male, 59% were Caucasian and 23% were Black. The mean baseline CD4<span class="Sup">+</span> cell count was 245 cells/mm<span class="Sup">3</span> (range 2–1191) and median baseline plasma HIV-1 RNA was 5.01 log<span class="Sub">10</span> copies/mL (range 3.56–6.54). Subjects were stratified by baseline CD4<span class="Sup">+</span> cell count (&lt; or ≥ 200 cells/mm<span class="Sup">3</span>) and 41% had CD4<span class="Sup">+</span> cell counts &lt;200 cells/mm<span class="Sup">3</span>. Fifty-one percent (51%) of subjects had baseline viral loads &gt;100,000 copies/mL. Treatment outcomes through 48 and 144 weeks for those subjects who did not have efavirenz resistance at baseline (n=487) are presented in Table 10.</p>
<a name="table10"></a><table width="80%">
<caption><span>Table 10 Outcomes of Randomized Treatment at Weeks 48 and 144 (Study 934)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="middle">Outcomes</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 48</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 144</th>
</tr>
<tr class="Last">
<th align="center">FTC + TDF<br> +EFV<br> (N=244)</th>
<th class="Lrule Rrule" align="center">AZT/3TC<br> +EFV<br> (N=243)</th>
<th class="Rrule" align="center">FTC + TDF<br> +EFV<br> (N=227)<a name="footnote-reference-36" href="#footnote-36" class="Sup">*</a>
</th>
<th class="Rrule" align="center">AZT/3TC<br> +EFV<br> (N=229)<a href="#footnote-36" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-36" href="#footnote-reference-36">*</a></dt>
<dd>Subjects who were responders at Week 48 or Week 96 (HIV-1 RNA &lt;400 copies/mL) but did not consent to continue study after Week 48 or Week 96 were excluded from analysis.</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">†</a></dt>
<dd>Subjects achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">‡</a></dt>
<dd>Includes confirmed viral rebound and failure to achieve confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">§</a></dt>
<dd>Includes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other reasons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Responder<a name="footnote-reference-37" href="#footnote-37" class="Sup">†</a>
</td>
<td align="center">84%</td>
<td class="Lrule Rrule" align="center">73%</td>
<td class="Rrule" align="center">71%</td>
<td class="Rrule" align="center">58%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virologic failure<a name="footnote-reference-38" href="#footnote-38" class="Sup">‡</a>
</td>
<td align="center">2%</td>
<td class="Lrule Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Rebound</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Never suppressed</td>
<td align="center">0%</td>
<td class="Lrule Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change in antiretroviral regimen</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">&lt;1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Discontinued due to adverse event</td>
<td align="center">4%</td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinued for other reasons<a name="footnote-reference-39" href="#footnote-39" class="Sup">§</a>
</td>
<td align="center">10%</td>
<td class="Lrule Rrule" align="center">14%</td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">22%</td>
</tr>
</tbody>
</table>
<p>Through Week 48, 84% and 73% of subjects in the emtricitabine + tenofovir DF group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;400 copies/mL (71% and 58% through Week 144). The difference in the proportion of subjects who achieved and maintained HIV-1 RNA &lt;400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reasons in the zidovudine/lamivudine group in this open-label study. In addition, 80% and 70% of subjects in the emtricitabine + tenofovir DF group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;50 copies/mL through Week 48 (64% and 56% through Week 144). The mean increase from baseline in CD4<span class="Sup">+</span> cell count was 190 cells/mm<span class="Sup">3</span> in the emtricitabine + tenofovir DF group and 158 cells/mm<span class="Sup">3</span> in the zidovudine/lamivudine group at Week 48 (312 and 271 cells/mm<span class="Sup">3</span> at Week 144).</p>
<p>Through 48 weeks, 7 subjects in the emtricitabine + tenofovir DF group and 5 subjects in the zidovudine/lamivudine group experienced a new CDC Class C event (10 and 6 subjects through 144 weeks).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 073:</span> Study 073 was a 48-week open-label, randomized clinical trial in subjects with stable, virologic suppression on combination antiretroviral therapy consisting of at least two nucleoside reverse transcriptase inhibitors (NRTIs) administered in combination with a protease inhibitor (with or without ritonavir) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). </p>
<p>To be enrolled, subjects were to have HIV-1 RNA &lt;200 copies/mL for at least 12 weeks on their current regimen prior to study entry with no known HIV-1 substitutions conferring resistance to the components of ATRIPLA and no history of virologic failure. </p>
<p>The study compared the efficacy of switching to ATRIPLA or staying on the baseline antiretroviral regimen (SBR). Subjects were randomized in a 2:1 ratio to switch to ATRIPLA (N=203) or stay on SBR (N=97). Subjects had a mean age of 43 years (range 22 to 73 years), 88% were male, 68% were white, 29% were black or African-American, and 3% were of other races. At baseline, median CD4<span class="Sup">+</span> cell count was 516 cells/mm<span class="Sup">3</span> and 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral therapy was 3 years and 88% of subjects were receiving their first antiretroviral regimen at study enrollment.</p>
<p>At Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA &lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88% and 85% who remained on SBR; this difference was not statistically significant. No changes in CD4+ cell counts from baseline to Week 48 were observed in either treatment arm.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ATRIPLA tablets are pink, capsule-shaped, film-coated, debossed with "123" on one side and plain-faced on the other side. </p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source NDC</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0208-1</td>
<td align="center">600 mg / 200 mg / 300 mg</td>
<td align="center">30 TABLET</td>
<td align="center">PINK</td>
<td align="center">15584-0101-1</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First">Store at 25 °C (77 °F); excursions permitted to 15–30 °C (59–86 °F) [see USP Controlled Room Temperature].</p>
<ul>
<li>Keep container tightly closed.</li>
<li>Dispense only in original container.</li>
<li>Do not use if seal over bottle opening is broken or missing.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION and FDA-APPROVED PATIENT LABELING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Drug Interactions</h2>
<p class="First">A statement to patients and healthcare providers is included on the product's bottle labels:  <span class="Italics">ALERT: Find out about medicines that should NOT be taken with ATRIPLA. </span>ATRIPLA may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, nonprescription medication, or herbal products, particularly St. John's wort.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Information for Patients</h2>
<p class="First">Patients should be advised that:</p>
<ul>
<li>ATRIPLA is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and that they may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using ATRIPLA.</li>
<li>The use of ATRIPLA has not been shown to reduce the risk of transmission of HIV-1 to others through sexual contact or blood contamination. Patients should be advised to continue to practice safer sex and to use latex or polyurethane condoms to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions or blood. Patients should be advised never to re-use or share needles.</li>
<li>The long term effects of ATRIPLA are unknown.</li>
<li>Redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known.</li>
<li>ATRIPLA should not be coadministered with SUSTIVA, EMTRIVA, VIREAD, or TRUVADA, or drugs containing lamivudine, including Combivir, Epivir, Epivir-HBV, Epzicom, or Trizivir.</li>
<li>ATRIPLA should not be administered with HEPSERA <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First">Patients should be informed that <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported. Treatment will be suspended in any patients who develop clinical symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4	Patients Coinfected with HIV-1 and HBV</h2>
<p class="First">Patients with HIV-1 should be tested for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) before initiating antiretroviral therapy. </p>
<p>Patients should be advised that severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued EMTRIVA (emtricitabine) or VIREAD (tenofovir DF), which are components of ATRIPLA. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, has been reported. ATRIPLA should be avoided with concurrent or recent use of a nephrotoxic agent <span class="Italics">[See <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6	Decreases in Bone Mineral Density</h2>
<p class="First">Patients should be informed that decreases in bone mineral density have been observed with the use of tenofovir DF. Bone mineral density monitoring may be performed in patients who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span> <span class="Italics">[See <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7	Dosing Instructions</h2>
<p class="First">Patients should be advised to take ATRIPLA orally on an empty stomach and that it is important to take ATRIPLA on a regular dosing schedule to avoid missing doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8	Nervous System Symptoms</h2>
<p class="First">Patients should be informed that central nervous system symptoms (NSS) including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, impaired concentration, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span> are commonly reported during the first weeks of therapy with efavirenz. Dosing at bedtime may improve the tolerability of these symptoms, which are likely to improve with continued therapy. Patients should be alerted to the potential for additive effects when ATRIPLA is used concomitantly with alcohol or psychoactive drugs. Patients should be instructed that if they experience NSS they should avoid potentially hazardous tasks such as driving or operating machinery <span class="Italics">[See <a href="#S5.6">Warnings and Precautions (5.6)</a>, and <a href="#S2">Dosage and Administration (2)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.9"></a><a name="section-15.9"></a><p></p>
<h2>17.9	<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></h2>
<p class="First">Patients should be informed that serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> including severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>-like symptoms have been reported in patients receiving efavirenz. If they experience severe psychiatric adverse experiences they should seek immediate medical evaluation. Patients should be advised to inform their physician of any history of mental illness or <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.10"></a><a name="section-15.10"></a><p></p>
<h2>17.10	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">Patients should be informed that a common side effect is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> usually go away without any change in treatment. However, since <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be serious, patients should be advised to contact their physician promptly if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.11"></a><a name="section-15.11"></a><p></p>
<h2>17.11	Reproductive Risk Potential</h2>
<p class="First">Women receiving ATRIPLA should be instructed to avoid pregnancy <span class="Italics">[See <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>. A reliable form of barrier contraception must always be used in combination with other methods of contraception, including oral or other hormonal contraception. Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of ATRIPLA is recommended.  Women should be advised to notify their physician if they become pregnant or plan to become pregnant while taking ATRIPLA. If this drug is used during the first trimester of pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential harm to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">Patient Information</span></p>
<p><span class="Bold">ATRIPLA<span class="Sup">®</span> (uh TRIP luh) Tablets</span></p>
<p><span class="Bold">ALERT:  Find out about medicines that should NOT be taken with ATRIPLA.</span></p>
<p>Please also read the section <span class="Bold">"MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA."</span></p>
<p>Generic name: efavirenz, emtricitabine and tenofovir disoproxil fumarate<br>(eh FAH vih renz, em tri SIT uh bean and te NOE' fo veer dye soe PROX il FYOU mar ate)</p>
<p>Read the Patient Information that comes with ATRIPLA before you start taking it and each time you get a refill since there may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. You should stay under a healthcare provider's care when taking ATRIPLA. <span class="Bold">Do not change or stop your medicine without first talking with your healthcare provider. </span>Talk to your healthcare provider or pharmacist if you have any questions about ATRIPLA.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about ATRIPLA?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Some people who have taken medicine like ATRIPLA (which contains nucleoside analogs) have developed a serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span></span> (build up of an acid in the blood). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be a medical emergency and may need to be treated in the hospital. <span class="Bold">Call your healthcare provider right away if you get the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span><ul class="Disc">
<li>You feel very weak or tired.</li>
<li>You have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>.</li>
<li>You have trouble breathing.</li>
<li>You have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</li>
<li>You feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs.</li>
<li>You feel dizzy or lightheaded.</li>
<li>You have a fast or irregular heartbeat.</li>
</ul>
</li>
<li>
<span class="Bold">Some people who have taken medicines like ATRIPLA have developed serious liver problems called hepatotoxicity</span>, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). <span class="Bold">Call your healthcare provider right away if you get the following signs or symptoms of liver problems:</span><ul class="Disc">
<li>Your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>).</li>
<li>Your urine turns dark.</li>
<li>Your bowel movements (stools) turn light in color.</li>
<li>You don't feel like eating food for several days or longer.</li>
<li>You feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</li>
<li>You have lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</li>
</ul>
</li>
<li>
<span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or liver problems</span> if you are female, very overweight (obese), or have been taking nucleoside analog-containing medicines, like ATRIPLA, for a long time.</li>
<li>
<span class="Bold">If you also have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and you stop taking ATRIPLA, you may get a "flare-up" of your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. A "flare-up" is when the disease suddenly returns in a worse way than before. </span>Patients with HBV who stop taking ATRIPLA need close medical follow-up for several months, including medical exams and blood tests to check for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> that could be getting worse. ATRIPLA is not approved for the treatment of HBV, so you must discuss your HBV therapy with your healthcare provider.</li>
</ul>
<p><span class="Bold">What is ATRIPLA?</span></p>
<p>ATRIPLA contains 3 medicines, SUSTIVA<span class="Sup">®</span> (efavirenz), EMTRIVA<span class="Sup">®</span> (emtricitabine) and VIREAD<span class="Sup">®</span> (tenofovir disoproxil fumarate also called tenofovir DF) combined in one pill. EMTRIVA and VIREAD are HIV-1 (human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus) nucleoside analog reverse transcriptase inhibitors (NRTIs) and SUSTIVA is an HIV-1 non-nucleoside analog reverse transcriptase inhibitor (NNRTI). VIREAD and EMTRIVA are the components of TRUVADA<span class="Sup">®</span>. ATRIPLA can be used alone as a complete regimen, or in combination with other anti-HIV-1 medicines to treat people with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. ATRIPLA is for adults age 18 and over. ATRIPLA has not been studied in children under age 18 or adults over age 65.</p>
<p><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> destroys CD4<span class="Sup">+</span> T cells, which are important to the immune system. The immune system helps fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. After a large number of T cells are destroyed, <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> (AIDS) develops.</p>
<p>ATRIPLA helps block HIV-1 reverse transcriptase, a viral chemical in your body (enzyme) that is needed for HIV-1 to multiply. ATRIPLA lowers the amount of HIV-1 in the blood (viral load). ATRIPLA may also help to increase the number of T cells (CD4<span class="Sup">+</span> cells), allowing your immune system to improve. Lowering the amount of HIV-1 in the blood lowers the chance of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<p><span class="Bold">Does ATRIPLA cure HIV-1 or AIDS?</span></p>
<p><span class="Bold">ATRIPLA does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS. </span>The long-term effects of ATRIPLA are not known at this time. People taking ATRIPLA may still get <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> or other conditions that happen with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that develop because the immune system is weak. Some of these conditions are <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span>, and <span class="Italics">Mycobacterium avium complex</span> (MAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="Bold">It is very important that you see your healthcare provider regularly while taking ATRIPLA.</span></p>
<p><span class="Bold">Does ATRIPLA reduce the risk of passing HIV-1 to others?</span></p>
<p><span class="Bold">ATRIPLA has not been shown to lower your chance of passing HIV-1 to other people through sexual contact, sharing needles, or being exposed to your blood.</span></p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes or razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection. </span>Always practice safer sex by using a latex or polyurethane condom or other barrier to reduce the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p><span class="Bold">Who should not take ATRIPLA?</span></p>
<p>Together with your healthcare provider, you need to decide whether ATRIPLA is right for you.</p>
<p>Do not take ATRIPLA if you are allergic to ATRIPLA or any of its ingredients. The active ingredients of ATRIPLA are efavirenz, emtricitabine, and tenofovir DF. See the end of this leaflet for a complete list of ingredients.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking ATRIPLA?</span></p>
<p><span class="Bold">Tell your healthcare provider if you:</span></p>
<ul>
<li>
<span class="Bold">Are pregnant or planning to become pregnant</span> (see "<a href="#avoid">What should I avoid while taking ATRIPLA</a>?").</li>
<li>
<span class="Bold">Are breastfeeding</span> (see "<a href="#avoid">What should I avoid while taking ATRIPLA</a>?").</li>
<li><span class="Bold">Have kidney problems or are undergoing kidney dialysis treatment.</span></li>
<li><span class="Bold">Have bone problems.</span></li>
<li>
<span class="Bold">Have liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span> Your healthcare provider may want to do tests to check your liver while you take ATRIPLA.</li>
<li><span class="Bold">Have ever had mental illness or are using drugs or alcohol.</span></li>
<li><span class="Bold">Have ever had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or are taking medicine for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</span></li>
</ul>
<p><span class="Bold">What important information should I know about taking other medicines with ATRIPLA?</span></p>
<p><span class="Bold">ATRIPLA may change the effect of other medicines, including the ones for HIV-1, and may cause serious side effects. </span>Your healthcare provider may change your other medicines or change their doses. Other medicines, including herbal products, may affect ATRIPLA. For this reason, <span class="Bold">it is very important to </span>let all your healthcare providers and pharmacists know what medications, herbal supplements, or vitamins you are taking.</p>
<p><span class="Bold">MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA</span></p>
<ul>
<li>The following medicines may cause serious and life-threatening side effects when taken with ATRIPLA. You should not take any of these medicines while taking ATRIPLA: Vascor (bepridil), Propulsid (cisapride), Versed (midazolam), Orap (pimozide), Halcion (triazolam), ergot medications (for example, Wigraine and Cafergot).</li>
<li>ATRIPLA also should not be used with Combivir (lamivudine/zidovudine), EMTRIVA, Epivir, Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), Trizivir (abacavir sulfate/lamivudine/zidovudine), SUSTIVA, TRUVADA, or VIREAD.</li>
<li>Vfend (voriconazole) should not be taken with ATRIPLA since it may lose its effect or may increase the chance of having side effects from ATRIPLA.</li>
<li>
<span class="Bold">Do not take St. John's wort (<span class="Italics">Hypericum perforatum</span>), or products containing St. John's wort with ATRIPLA. </span>St. John's wort is an herbal product sold as a dietary supplement. Talk with your healthcare provider if you are taking or are planning to take St. John's wort. Taking St. John's wort may decrease ATRIPLA levels and lead to increased viral load and possible resistance to ATRIPLA or cross-resistance to other anti-HIV-1 drugs.</li>
<li>ATRIPLA should not be used with HEPSERA<span class="Sup">®</span> (adefovir dipivoxil). </li>
</ul>
<p>It is also important to tell your healthcare provider if you are taking any of the following:</p>
<ul>
<li>Fortovase, Invirase (saquinavir), Biaxin (clarithromycin); or Sporanox (itraconazole); <span class="Bold">these medicines may need to be replaced with another medicine when taken with ATRIPLA.</span>
</li>
<li>Calcium channel blockers such as Cardizem or Tiazac (diltiazem), Covera HS or Isoptin (verapamil) and others; Crixivan (indinavir); the immunosuppressant medicines cyclosporine (Gengraf, Neoral, Sandimmune, and others), Prograf (tacrolimus), or Rapamune (sirolimus); Methadone; Mycobutin (rifabutin); Rifampin; <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicines such as Lipitor (atorvastatin), Pravachol (pravastatin sodium), and Zocor (simvastatin); or Zoloft (sertraline); <span class="Bold">these medicines may need to have their dose changed when taken with ATRIPLA.</span>
</li>
<li>Videx, Videx EC (didanosine); tenofovir DF (a component of ATRIPLA) may increase the amount of didanosine in your blood, which could result in more side effects. <span class="Bold">You may need to be monitored more carefully</span> if you are taking ATRIPLA and didanosine together. Also, the dose of didanosine may need to be changed.</li>
<li>Reyataz (atazanavir sulfate) or Kaletra (lopinavir/ritonavir); these medicines may increase the amount of tenofovir DF (a component of ATRIPLA) in your blood, which could result in more side effects. Reyataz is not recommended with ATRIPLA. <span class="Bold">You may need to be monitored more carefully </span>if you are taking ATRIPLA and Kaletra together. Also, the dose of Kaletra may need to be changed.</li>
<li>Medicine for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [for example, Dilantin (phenytoin), Tegretol (carbamazepine), or phenobarbital]; your healthcare provider may want to switch you to another medicine or check drug levels in your blood from time to time.</li>
</ul>
<p><span class="Bold">These are not all the medicines that may cause problems if you take ATRIPLA. Be sure to tell your healthcare provider about all medicines that you take.</span></p>
<p>Keep a complete list of all the prescription and nonprescription medicines as well as any herbal remedies that you are taking, how much you take, and how often you take them. Make a new list when medicines or herbal remedies are added or stopped, or if the dose changes. Give copies of this list to all of your healthcare providers and pharmacists <span class="Bold">every</span> time you visit your healthcare provider or fill a prescription. This will give your healthcare provider a complete picture of the medicines you use. Then he or she can decide the best approach for your situation.</p>
<p><span class="Bold">How should I take ATRIPLA?</span></p>
<ul>
<li>Take the exact amount of ATRIPLA your healthcare provider prescribes. Never change the dose on your own. Do not stop this medicine unless your healthcare provider tells you to stop.</li>
<li>You should take ATRIPLA on an empty stomach.</li>
<li>Swallow ATRIPLA with water.</li>
<li>Taking ATRIPLA at bedtime may make some side effects less bothersome.</li>
<li>Do not miss a dose of ATRIPLA. If you forget to take ATRIPLA, take the missed dose right away, unless it is almost time for your next dose. Do not double the next dose. Carry on with your regular dosing schedule. If you need help in planning the best times to take your medicine, ask your healthcare provider or pharmacist.</li>
<li>If you believe you took more than the prescribed amount of ATRIPLA, contact your local poison control center or emergency room right away.</li>
<li>Tell your healthcare provider if you start any new medicine or change how you take old ones. Your doses may need adjustment.</li>
<li>When your ATRIPLA supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to ATRIPLA and become harder to treat.</li>
<li>Your healthcare provider may want to do blood tests to check for certain side effects while you take ATRIPLA.</li>
</ul>
<p><a name="avoid"></a><span class="Bold">What should I avoid while taking ATRIPLA?</span></p>
<ul>
<li>
<span class="Bold">Women should not become pregnant while taking ATRIPLA and for 12 weeks after stopping it. </span> Serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> have been seen in the babies of animals and women treated with efavirenz (a component of ATRIPLA) during pregnancy. It is not known whether efavirenz caused these defects. <span class="Bold">Tell your healthcare provider right away if you are pregnant. </span>Also talk with your healthcare provider if you want to become pregnant.</li>
<li>Women should not rely only on hormone-based birth control, such as pills, injections, or implants, because ATRIPLA may make these contraceptives ineffective.  Women must use a reliable form of barrier contraception, such as a condom or diaphragm, even if they also use other methods of birth control. Efavirenz, a component of ATRIPLA, may remain in your blood for a time after therapy is stopped. Therefore, you should continue to use contraceptive measures for 12 weeks after you stop taking ATRIPLA.</li>
<li>
<span class="Bold">Do not breast-feed if you are taking ATRIPLA. </span>The Centers for Disease Control and Prevention recommend that mothers with HIV not breast-feed because they can pass the HIV through their milk to the baby. Also, ATRIPLA may pass through breast milk and cause serious harm to the baby. Talk with your healthcare provider if you are breast-feeding. You should stop breast-feeding or may need to use a different medicine.</li>
<li>Taking ATRIPLA with alcohol or other medicines causing similar side effects as ATRIPLA, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, may increase those side effects.</li>
<li>Do not take any other medicines, including prescription and nonprescription medicines and herbal products, without checking with your healthcare provider.</li>
<li>
<span class="Bold">Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span> since ATRIPLA does not stop you from passing the HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ATRIPLA?</span></p>
<p><span class="Bold">ATRIPLA may cause the following serious side effects:</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span></span> (buildup of an acid in the blood). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be a medical emergency and may need to be treated in the hospital. <span class="Bold">Call your healthcare provider right away if you get signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. </span>(See "<a href="#important">What is the most important information I should know about ATRIPLA</a>?")</li>
<li>
<span class="Bold">Serious liver problems (hepatotoxicity)</span>, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). Call your healthcare provider right away if you get any signs of liver problems. (See "<a href="#important">What is the most important information I should know about ATRIPLA</a>?")</li>
<li>
<span class="Bold">"Flare-ups" of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span>, in which the disease suddenly returns in a worse way than before, can occur if you have HBV and you stop taking ATRIPLA. Your healthcare provider will monitor your condition for several months after stopping ATRIPLA if you have both HIV-1 and HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and may recommend treatment for your HBV. ATRIPLA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If you have advanced liver disease and stop treatment with ATRIPLA, the "flare-up" of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B may cause your liver function to decline.</li>
<li>
<span class="Bold">Serious psychiatric problems. </span>A small number of patients may experience severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, strange thoughts, or angry behavior while taking ATRIPLA. Some patients have thoughts of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> and a few have actually committed <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. These problems may occur more often in patients who have had mental illness. Contact your healthcare provider right away if you think you are having these <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, so your healthcare provider can decide if you should continue to take ATRIPLA.</li>
<li>
<span class="Bold">Kidney problems</span> (including decline or failure of kidney function)<span class="Bold">.</span> If you have had kidney problems in the past or take other medicines that can cause kidney problems, your healthcare provider should do regular blood tests to check your kidneys. Symptoms that may be related to kidney problems include a high volume of urine, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</li>
<li>
<span class="Bold">Changes in bone mineral density (thinning bones). </span>Laboratory tests show changes in the bones of patients treated with tenofovir DF, a component of ATRIPLA. Some HIV patients treated with tenofovir DF developed thinning of the bones (<span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>) which could lead to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. If you have had bone problems in the past, your healthcare provider may need to do tests to check your bone mineral density or may prescribe medicines to help your bone mineral density. Additionally, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and softening of the bone (which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) may occur as a consequence of kidney problems.</li>
</ul>
<p><span class="Bold">Common side effects: </span></p>
<p>Patients may have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, trouble sleeping, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, trouble concentrating, and/or unusual dreams during treatment with ATRIPLA. These side effects may be reduced if you take ATRIPLA at bedtime on an empty stomach. They also tend to go away after you have taken the medicine for a few weeks. If you have these common side effects, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, it does not mean that you will also have serious psychiatric problems, such as severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, strange thoughts, or angry behavior. Tell your healthcare provider right away if any of these side effects continue or if they bother you. It is possible that these symptoms may be more severe if ATRIPLA is used with alcohol or mood altering (street) drugs.</p>
<p>If you are dizzy, have trouble concentrating, or are drowsy, avoid activities that may be dangerous, such as driving or operating machinery.</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> may be common. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> usually go away without any change in treatment. In a small number of patients, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be serious. If you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, call your healthcare provider right away.</p>
<p>Other common side effects include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gas, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">Other possible side effects with ATRIPLA:</span></p>
<ul>
<li>Changes in body fat. Changes in body fat develop in some patients taking anti HIV-1 medicine. These changes may include an increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), in the breasts, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these fat changes are not known.</li>
<li><span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span> (small spots or freckles) may also happen with ATRIPLA.</li>
<li>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS), signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms. If you notice any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, please inform your doctor immediately.</li>
<li>Additional side effects are <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, or throat), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>.</li>
</ul>
<p>Tell your healthcare provider or pharmacist if you notice any side effects while taking ATRIPLA.</p>
<p>Contact your healthcare provider before stopping ATRIPLA because of side effects or for any other reason.</p>
<p>This is not a complete list of side effects possible with ATRIPLA. Ask your healthcare provider or pharmacist for a more complete list of side effects of ATRIPLA and all the medicines you will take.</p>
<p><span class="Bold">How do I store ATRIPLA?</span></p>
<ul>
<li><span class="Bold">Keep ATRIPLA and all other medicines out of reach of children.</span></li>
<li>Store ATRIPLA at room temperature 77 °F (25 °C).</li>
<li>Keep ATRIPLA in its original container and keep the container tightly closed.</li>
<li>Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away make sure that children will not find them.</li>
</ul>
<p><span class="Bold">General information about ATRIPLA:</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use ATRIPLA for a condition for which it was not prescribed. Do not give ATRIPLA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about ATRIPLA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ATRIPLA that is written for health professionals.</p>
<p>Do not use ATRIPLA if the seal over bottle opening is broken or missing.</p>
<p><span class="Bold">What are the ingredients of ATRIPLA?</span></p>
<p><span class="Bold">Active Ingredients:</span>  efavirenz, emtricitabine, and tenofovir disoproxil fumarate </p>
<p><span class="Bold">Inactive Ingredients:</span>  croscarmellose sodium, hydroxypropyl cellulose, microcrystalline cellulose, magnesium stearate, sodium lauryl sulfate. The film coating contains black iron oxide, polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, and titanium dioxide.</p>
<p><span class="Bold">R<span class="Sub">x</span> Only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First">ATRIPLA is a trademark of Bristol-Myers Squibb &amp; Gilead Sciences, LLC. EMTRIVA, TRUVADA, HEPSERA and VIREAD are trademarks of Gilead Sciences, Inc. SUSTIVA is a trademark of Bristol-Myers Squibb Pharma Company. Reyataz and Videx are trademarks of Bristol-Myers Squibb Company. Pravachol is a trademark of ER Squibb &amp; Sons, LLC. Other brands listed are the trademarks of their respective owners.</p>
<p>This product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</span></p>
<p>NDC 53808-0208-1</p>
<p><span class="Bold">ATRIPLA<span class="Sup">®</span></span></p>
<p><span class="Bold">(efavirenz 600 mg/emtricitabine 200 mg/<br>tenofovir disoproxil fumarate 300 mg)<br>Tablets</span></p>
<p>30 tablets</p>
<p><span class="Bold">Note to pharmacist: Do not cover ALERT box with pharmacy label.</span></p>
<p><span class="Bold">ALERT: Find out about medicines that<br>  should NOT be taken with ATRIPLA<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=076da359-b3d0-44f7-8c0e-662f5b7a8668&amp;name=Atripla.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATRIPLA 		
					</strong><br><span class="contentTableReg">efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0208(NDC:15584-0101)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EFAVIRENZ</strong> (efavirenz) </td>
<td class="formItem">EFAVIRENZ</td>
<td class="formItem">600 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>EMTRICITABINE</strong> (emtricitabine) </td>
<td class="formItem">EMTRICITABINE</td>
<td class="formItem">200 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TENOFOVIR DISOPROXIL FUMARATE</strong> (Tenofovir) </td>
<td class="formItem">TENOFOVIR DISOPROXIL FUMARATE</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">123</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0208-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021937</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ff0cb213-2f3d-40c6-9465-e32d465a24e2</div>
<div>Set id: 076da359-b3d0-44f7-8c0e-662f5b7a8668</div>
<div>Version: 2</div>
<div>Effective Time: 20100312</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
